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Abstract
The human immunodeficiency virus (HIV) affects millions of people worldwide who rely on antiretroviral
therapy to prevent the acquired immunodeficiency syndrome and halt further HIV transmission. HIV
integrase (IN), one of the three retroviral enzymes, catalyzes the covalent insertion of a DNA copy of the
HIV genome into host cell chromatin, an essential step in the viral replication cycle. Integration enables
expression of a new generation of viral RNA genomes and subgenomic RNAs encoding viral proteins, and
establishes the potential for latency, a major barrier to cure. Despite being considered initially to be
“undruggable”, IN has been successfully targeted with small-molecule therapeutics, two classes of which
are studied here. The strand transfer inhibitors (STIs), which block an essential step in IN catalysis, are
FDA-approved and in widespread clinical use. Clinical resistance to STIs has been documented,
motivating the design of new generations of STIs with high genetic barriers to resistance and novel
approaches to targeting IN. The allosteric inhibitors of integrase (ALLINIs) bind to a site distinct from STIs
and do not directly block catalysis, instead act by aberrantly polymerizing IN, disrupting virion maturation.
The binding interface of ALLINIs and a structural explanation of their mechanism of action was recently
reported by our group. Accurate structural and biochemical data are essential for ongoing drug
development and efforts to understand mechanisms of resistance. Here, we report structural and
biochemical advances that further our understanding of antiretrovirals targeting HIV IN. We have
improved the resolution of structural models of IN·ALLINI polymers, extended these data to multiple
members of this class of compounds, and revealed mechanisms of resistance. We have identified a
promising clinical opportunity combining ALLINIs and STIs that exploits the hypersensitivity of STIresistant IN to ALLINI inhibition. Through the creation of an improved in vitro model, we report structural
and biochemical data that most closely recapitulates the form of IN found in vivo. Finally, we report
progress toward structural and functional characterization of the catalytically active complex of IN and
viral DNA, the intasome. Together, this body of work advances our understanding of a key step in the
pathogenesis of HIV and provides a foundation for improvements to therapeutics.
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ABSTRACT
STRUCTURAL AND BIOCHEMICAL STUDIES OF HIV-1 INTEGRATION AND INHIBITION

Grant Eilers
Frederic D. Bushman and Gregory D. Van Duyne
The human immunodeficiency virus (HIV) affects millions of people worldwide
who rely on antiretroviral therapy to prevent the acquired immunodeficiency syndrome
and halt further HIV transmission. HIV integrase (IN), one of the three retroviral
enzymes, catalyzes the covalent insertion of a DNA copy of the HIV genome into host
cell chromatin, an essential step in the viral replication cycle. Integration enables
expression of a new generation of viral RNA genomes and subgenomic RNAs encoding
viral proteins, and establishes the potential for latency, a major barrier to cure. Despite
being considered initially to be “undruggable”, IN has been successfully targeted with
small-molecule therapeutics, two classes of which are studied here. The strand transfer
inhibitors (STIs), which block an essential step in IN catalysis, are FDA-approved and in
widespread clinical use. Clinical resistance to STIs has been documented, motivating
the design of new generations of STIs with high genetic barriers to resistance and novel
approaches to targeting IN. The allosteric inhibitors of integrase (ALLINIs) bind to a site
distinct from STIs and do not directly block catalysis, instead act by aberrantly
polymerizing IN, disrupting virion maturation. The binding interface of ALLINIs and a
structural explanation of their mechanism of action was recently reported by our group.
Accurate structural and biochemical data are essential for ongoing drug development
and efforts to understand mechanisms of resistance. Here, we report structural and
biochemical advances that further our understanding of antiretrovirals targeting HIV IN.
We have improved the resolution of structural models of IN·ALLINI polymers, extended
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these data to multiple members of this class of compounds, and revealed mechanisms
of resistance. We have identified a promising clinical opportunity combining ALLINIs and
STIs that exploits the hypersensitivity of STI-resistant IN to ALLINI inhibition. Through
the creation of an improved in vitro model, we report structural and biochemical data that
most closely recapitulates the form of IN found in vivo. Finally, we report progress toward
structural and functional characterization of the catalytically active complex of IN and
viral DNA, the intasome. Together, this body of work advances our understanding of a
key step in the pathogenesis of HIV and provides a foundation for improvements to
therapeutics.
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Chapter 1: Introduction
1.1 Human immunodeficiency virus and antiretroviral therapy
The origin of the human immunodeficiency virus (HIV) can be clearly traced to
zoonotic transmission from non-human primates to humans in the early 1900s (Keele et
al. 2006; Faria et al. 2014). HIV spread undetected until the 1980s, when clusters of
cases of unexplained immunodeficiency (Gottlieb et al. 1981; Masur et al. 1981)
launched a search for a causative agent. The virus was identified shortly thereafter
(Barré-Sinoussi et al. 1983; Gallo et al. 1983), and determined to be the cause of the
acquired immune deficiency syndrome (AIDS) through infection and depletion of CD4+ T
cells and systemic immune dysfunction (Moir, Chun, and Fauci 2011; McCune 2001).
HIV has infected approximately 75 million people worldwide (“UNAIDS Data 2019”
2019), and approximately 32 million people have died from AIDS-related illnesses. It
remains a major cause of morbidity and mortality today (Roth et al. 2018).
The first antiretroviral drug, zidovudine (3′-azido-3′-deoxythymidine or AZT)
inhibited reverse transcription and was approved in 1987 (Mitsuya et al. 1985; Fischl et
al. 1987). It was quickly recognized that a single drug would not effectively control HIV
(Larder, Darby, and Richman 1989), spurring the development of combination regimens
(Hammer et al. 1996) that are the current paradigm of antiretroviral therapy (Arts and
Hazuda 2012). An arsenal of antiretroviral therapeutics targeting multiple steps of the
viral replication cycle are available today, and play a major role in mitigating the effects
of HIV. The last few years have seen a reduction in the number of new HIV infections
and AIDS-related deaths (“UNAIDS Data 2019” 2019), underscoring the success of
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antiretroviral therapy. However, many HIV infections remain undiagnosed and millions of
people still lack access to antiretroviral therapy, emphasizing the importance of
continued research and development in this area.
Although antiretroviral drugs have been developed to target nearly every step in
the viral replication cycle, the most commonly used drugs target the three viral enzymes:
protease, reverse transcriptase, and integrase (Arts and Hazuda 2012). Although
integrase was the last enzyme to be successfully targeted (D. J. Hazuda, Anthony, et al.
2004; Espeseth et al. 2000; D. J. Hazuda, Young, et al. 2004), integrase inhibitors are
now in widespread clinical use (A. N. Engelman 2019; Mesplède and Wainberg 2013),
and are included in the recommended initial ART regimens (Günthard et al. 2016;
“AIDSinfo” 2019; World Health Organization 2018). Research directed toward
antiretroviral therapy targeting HIV integrase (the topic of this thesis) will directly benefit
the ongoing battle against the morbidity and mortality of the HIV/AIDS epidemic.

1.2 HIV integration and integrase
After entering a host cell and completing the process of reverse transcription, the
HIV genome enters the nucleus to be integrated into host chromatin (Robert Craigie and
Bushman 2012). This process is an essential step in the retroviral replication cycle,
allowing for the production of viral proteins and the transcription of viral genome copies
to form another generation of virions (Varmus 1988). The integrated provirus is
replicated along with the host cell genome, establishing the potential for latency, a major
barrier to the cure of HIV.
Integration is catalyzed by the retroviral integrase enzyme in two steps, 3’
processing and strand transfer (Fujiwara and Mizuuchi 1988; Brown et al. 1989; A.
2

Engelman, Mizuuchi, and Craigie 1991). In the first step, 3’-processing, integrase
cleaves two nucleotides from the 3’ end of the viral DNA, leaving the conserved 5’-CA-3’
sequence. In the second step, the newly exposed 3’ hydroxyl group attacks the
phosphate backbone of host cell DNA, leading to the covalent insertion of the viral DNA.
Both reactions are transesterification reactions breaking phosphodiester bonds through
nucleophilic attack (Delelis et al. 2008). In 3’-processing, the phosphodiester bond is in
the viral DNA and the nucleophile is a water molecule. In strand transfer, the
phosphodiester bond is in the host cell DNA, and the nucleophile is the newly-exposed
3’ hydroxyl group of the viral DNA. Strand transfer must occur at both viral DNA ends for
productive integration, a process termed “concerted” integration. The resulting
symmetrical gaps and overhangs are repaired by host cell enzymes (Brin et al. 2000).
Both steps of the integration reaction can be reproduced in vitro (Leh et al. 2000; M. Li et
al. 2006; M. Li and Craigie 2005; Sinha, Pursley, and Grandgenett 2002; Sinha and
Grandgenett 2005; Bushman and Craigie 1991; Bushman, Fujiwara, and Craigie 1990;
Hindmarsh et al. 1999). Integrase has additional roles in the viral replication cycle, and
likely many more that remain undiscovered, but they are not covered in detail here. One
particular auxiliary role, relevant for virion maturation, will be mentioned in a subsequent
section.
The integrase enzyme is produced by proteolysis of the Gag-Pol polyprotein by
the retroviral protease. Its 288 amino acids fold into three domains: the N-terminal
(NTD), catalytic core (CCD), and C-terminal (CTD) domains (X. Li et al. 2011; A.
Engelman and Craigie 1992). The NTD adopts a zinc-finger fold through a conserved
and functionally essential HHCC motif (Mengli Cai et al. 1997; Zheng, Jenkins, and
Craigie 1996; Z. Zhao et al. 2008). The CCD contains the active site, a D,D-35-E motif
3

within an RNase H-like fold that coordinates divalent metal ions (A. Engelman and
Craigie 1992; Kulkosky et al. 1992; Dyda et al. 1994; Wielens et al. 2010). Integrase
activity depends on the presence of the divalent metal ionic cofactor (Mg2+ or Mn2+),
coordinated by the D,D-35-E motif (Goldgur et al. 1998; Maignan et al. 1998). The CCD
also contributes to DNA binding (T. M. Jenkins et al. 1997; Esposito and Craigie 1998;
Heuer and Brown 1997; Drake et al. 1998; A. A. Johnson et al. 2006). The CTD binds
DNA through its SH3-like fold (J. C.-H. Chen et al. 2000; Eijkelenboom et al. 1999).
Dimers of the NTD and CTD have been observed (Mengli Cai et al. 1997; Eijkelenboom
et al. 1999, 1995; Lodi et al. 1995), but the extensive CCD dimerization interface is the
best characterized and is expected to dictate the state of IN in vivo (Dyda et al. 1994).
However, integrase has been reported to exist in a wide range of multimeric forms (Hare,
Di Nunzio, et al. 2009; A. Engelman, Bushman, and Craigie 1993; Peter Cherepanov et
al. 2003; Faure et al. 2005; McKee et al. 2008; Pandey, Bera, and Grandgenett 2011).
Importantly, although a CCD dimer carries two active sites, the spacing between these
sites is incompatible with the spacing between sites of concerted integration. Long
before molecular models were available, the active form of integrase was suspected to
be a tetramer at minimum (Faure et al. 2005; M. Li et al. 2006; Bera et al. 2009; Hare, Di
Nunzio, et al. 2009), with some evidence of larger forms (Bera et al. 2009; Heuer and
Brown 1998; Peter Cherepanov et al. 2003).

1.3 Intasome structure
The active form of integrase was initially characterized through purification of
viral replication intermediates from infected cells (Farnet and Haseltine 1990; Ellison et
al. 1990; Bowerman et al. 1989). These intermediates, termed preintegration complexes
4

(PICs) contain multiple subunits of integrase, the viral DNA, and several other viral and
host cell proteins

(M. D. Miller, Farnet, and Bushman 1997; Bukrinsky et al. 1993;

Nermut and Fassati 2003). However, examination of PICs, integration reaction products,
and the structure of isolated domains did not elucidate the molecular structure of the
active integrase complex, although many models were proposed (Chiu and Davies 2004;
Jaskolski et al. 2009). Determination of the structure of the integrase-DNA complex (the
intasome) from the prototype foamy virus (Hare, Gupta, et al. 2010; G. N. Maertens,
Hare, and Cherepanov 2010) was a major breakthrough in the understanding of
integrase structure and function (Figure 1.1). The prototype foamy virus intasome is a
tetramer of integrase subunits assembled on the two viral DNA ends. The CCD
dimerization interface is essentially identical to that observed with the isolated domains,
so the intasome forms what is essentially a dimer-of-dimers. The complex consists of
extensive protein-DNA and protein-protein contacts, offering a structural context to
explain the regions of integrase implicated in DNA binding (T. M. Jenkins et al. 1997;
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Esposito and Craigie 1998; Heuer and Brown 1997; Drake et al. 1998; A. A. Johnson et
al. 2006). Although the core of the intasome (the region immediately surrounding the
catalytic sites) is well-resolved, domains located distally are not fully resolved, leaving
unanswered questions about their function.
Now that the structures of other retroviruses have been determined, the
prototype foamy virus intasome can be viewed as the simplest assembly of integrase
subunits on the viral DNA ends (Ballandras-Colas et al. 2017). Subsequent structures
revealed higher order forms present in viruses closely related to HIV (Figure 1.1)
(Ballandras-Colas et al. 2016; Yin et al. 2016; Ballandras-Colas et al. 2017; Cook et al.
2020), culminating in the determination of the HIV intasome itself (Passos et al. 2017,
2020). What remained relatively constant across all retroviral intasomes was the core
intasome structure that contains the active sites, important for understanding the
function of the strand transfer inhibitors (which will be discussed in more detail later) (A.
N. Engelman and Cherepanov 2017). Due to differences in domain architecture and
intra-domain linker length, however, the domains comprising the core intasome structure
are contributed by different integrase subunits across retroviruses.
The HIV-1 intasome has proven most recalcitrant to structural determination, in
spite of significant effort due to its clinical importance. In contrast to other retroviruses,
study of the HIV-1 intasome has been met with significant challenges. HIV-1 integrase
suffers from poor solubility and low activity in vitro (Peter Cherepanov et al. 2003; Hare,
Shun, et al. 2009; M. Li et al. 2014). Intasome preparations have resulted in
difficult-to-interpret heterogeneous results (Passos et al. 2017; M. Li et al. 2014). These
difficulties have been bypassed though the fusion of a small DNA-binding domain to the
NTD of integrase (M. Li et al. 2014), allowing for determination of the first HIV-1
6

intasome structures (Passos et al. 2017, 2020). The best-resolved intasome species is a
tetramer, which not surprising since the fusion of a DNA-binding domain to the N
terminus of integrase mimics the N-terminal extension domain present in the prototype
foamy virus integrase, which forms tetrameric intasomes. Additional higher-order
intasomes were also observed in the HIV-1 data, with stoichiometries similar to that of
the maedi-visna virus intasome, which consists of 16 subunits of integrase
(Ballandras-Colas et al. 2017). The core intasome structure of HIV-1 is highly similar to
the prototype foamy virus, facilitating the optimization of the strand transfer inhibitors, but
there is still an unmet need for structures of the native HIV-1 intasome.

1.4 Integrase strand transfer inhibitors
The initial development of integrase inhibitors was carried out in the absence of
molecular models of the intasome (Eric Deprez et al. 2004; D. J. Hazuda et al. 2000;
Egbertson 2007; Semenova, Marchand, and Pommier 2008). Due to their primary effect
on strand transfer, and comparatively minor effect on 3’ processing, these compounds
were termed strand transfer inhibitors (STIs), and presumed to bind to integrase in the
strand transfer complex, a form of the intasome that includes both the viral DNA and the
host cell DNA. Not until the prototype foamy virus intasome structure was revealed was
the mechanism of action of STIs made clear (Hare, Gupta, et al. 2010; G. N. Maertens,
Hare, and Cherepanov 2010; Hare, Vos, et al. 2010). These compounds bind in the
active site, coordinate the catalytic divalent metal cations, and displace the 3’ end of the
viral DNA, preventing nucleophilic attack of the host cell DNA. Due to differences in
domain architecture, intasome stoichiometry, and sensitivity to STIs between prototype
foamy virus and HIV (Grawenhoff and Engelman 2017; Valkov et al. 2009), significant
7

effort was invested in obtaining equivalent HIV intasome and intasome·inhibitor
structures. Ultimately, these structures were obtained through protein engineering and
Cryo-EM (Passos et al. 2017, 2020; M. Li et al. 2014). The HIV structures differ slightly
from the prototype foamy virus structures, although, structurally, the active site is highly
conserved. The HIV intasome structures illuminate pathways for increasing drug potency
and combating mechanisms of resistance.
STIs have been successful clinically (A. N. Engelman 2019; Mesplède and
Wainberg 2013) and now make up the first-line treatment for HIV (Günthard et al. 2016;
“AIDSinfo” 2019; World Health Organization 2018). Currently, four compounds,
raltegravir (Summa et al. 2008), elvitegravir (Sato et al. 2006), dolutegravir (Kobayashi
et al. 2011), and bictegravir (Tsiang et al. 2016) are FDA-approved. As with all classes of
antiretrovirals, resistance is a major barrier to durable effectiveness of the STIs
(Mesplède, Quashie, and Wainberg 2012; Wainberg, Mesplède, and Quashie 2012;
Geretti, Armenia, and Ceccherini-Silberstein 2012). Resistance to one STI often conveys
resistance to other members of the class (D. J. Hazuda, Anthony, et al. 2004; Garrido et
al. 2012). Optimized compounds show increased potency and higher barriers to
resistance (Tsiang et al. 2016; Naidu et al. 2018; Wiscount et al. 2008; Métifiot et al.
2011; X. Z. Zhao et al. 2016, 2017; Smith et al. 2018), often achieved by rational
optimization of inhibitor binding within the intasome active site. Therefore, detailed
structural models of the HIV intasome are essential determine differences between the
prototype foamy virus and HIV and to dissect mechanisms of resistance, enabling further
development of the STIs (Passos et al. 2020). Faced with viral resistance, alternative
approaches to targeting integrase are also needed.
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1.5 LEDGF and allosteric integrase inhibitors
One alternative approach to targeting integrase was discovered from a study of
interactions with host cell proteins. The best-characterized integrase-interacting host cell
proteins is the lens epithelium-derived growth factor (LEDGF), a protein normally
involved in transcription (Ge, Si, and Roeder 1998). LEDGF was identified in several
studies to interact with integrase (Peter Cherepanov et al. 2003; Turlure et al. 2004;
Emiliani et al. 2005), and through DNA- and chromatin-binding domains is able to recruit
integrase to genomic DNA (G. Maertens et al. 2003). Knockdown of LEDGF decreased
the infectivity of HIV in vitro, specifically affecting integration (Llano, Vanegas, et al.
2006; Shun et al. 2007; Emiliani et al. 2005; Busschots et al. 2007; Hombrouck et al.
2007). After knockdown, integration events were no longer focused in actively
transcribed regions of the genome, a phenotype that could be rescued by reintroduction
of LEDGF (Ciuffi et al. 2005; Marshall et al. 2007; Shun et al. 2007). Conversely,
overexpression of the integrase binding domain (IBD) of LEDGF separate from the
DNA-binding domains also inhibited integration (De Rijck et al. 2006; Llano, Saenz, et al.
2006), by competing with endogenous full-length LEDGF and modulating the oligomeric
state of integrase (Peter Cherepanov et al. 2003; Gupta et al. 2010; McKee et al. 2008;
Hare, Di Nunzio, et al. 2009). These observations led to investigation of the
LEDGFIBD·integrase interaction as a target for drug development (Llano, Saenz, et al.
2006; Peter Cherepanov et al. 2005).
The LEDGFIBD binds to a well-characterized site at the CCD dimerization
interface (Figure 1.2) (Peter Cherepanov et al. 2005; Hare, Shun, et al. 2009). Through
examination of available co-crystal structures and mimicry of the interacting residues on

9

LEDGF, small molecules were developed to interfere with the integrase·LEDGFIBD
interaction (Figure 1.2) (Christ et al. 2010). These compounds contained molecular
mimics of the key LEDGF residues that interact with integrase: a carboxyl moiety in
place of Asp-366, a phenyl group in place of Ile-365, and a chlorinated quinoline in place
of Leu-368. A hydrophobic tert-butoxy moiety was found to be an improvement over the
propyl moiety used in the first compounds (Christ et al. 2012), and is buried deeply in a
hydrophobic pocket along the CCD ɑ1 helix. Notably, this site had been identified as a
potential inhibitor binding site before it was known to be the site of LEDGF binding
(Molteni et al. 2001). Multiple groups have synthesized and characterized ALLINIs
(Fader et al. 2014; H. Wang et al. 2012; G. Li et al. 2020; Kessl et al. 2012; Sharma et
al. 2014; Tsiang et al. 2012; Amadori et al. 2017; Gupta et al. 2014; Wilson et al. 2019;
Peese et al. 2019), although all members of this class retain the same key features.

The effect of ALLINIs was expected to be similar to LEDGF knockdown or
LEDGFIBD overexpression, that is, inhibiting the integration step and redirecting
10

integration site specificity (Christ et al. 2010). Surprisingly, the major effect of ALLINIs
was observed to be late in the viral replication cycle, after integration into the host cell
genome had already occurred (Desimmie et al. 2013; Feng et al. 2013; Le Rouzic et al.
2013; Gupta et al. 2014; Slaughter et al. 2014). Although some activity is evident early in
viral replication, it is likely a secondary effect and not responsible for the potency of the
ALLINIs (Fontana et al. 2015; Balakrishnan et al. 2013; Sharma et al. 2014). The
phenotype observed was a virion maturation defect, leading to the production of
non-infectious virions containing abnormal, eccentric electron-dense aggregates
(Balakrishnan et al. 2013; Bonnard et al. 2018). Normal virion maturation is a complex
process that occurs as the newly budded virion containing all of the necessary
components for infection leaves the producer cell. Proteolytic processing of the Gag and
Gag-Pro-Pol polyproteins results in condensation of the viral RNA genome and
nucleocapsid into a central ribonucleoprotein complex surrounded by the capsid
(Sundquist and Kräusslich 2012). Disruption of this step by ALLINI treatment implicated
integrase in virion maturation (Kessl et al. 2016; Fontana et al. 2015; Tsiang et al. 2012).
Virions produced in the presence of ALLINIs contained mislocalized ribonucleoprotein
complexes and eccentrically-located aggregates of integrase (Jurado et al. 2013;
Fontana et al. 2015; Kessl et al. 2016). The cause of this phenotype was determined to
be abnormal multimerization of integrase by the ALLINIs (Jurado et al. 2013; Gupta et al.
2014; Desimmie et al. 2013; Feng et al. 2013; Gupta et al. 2016; Deng et al. 2016;
Koneru et al. 2019), preventing integrase from interacting with the viral RNA (Kessl et al.
2016).
The molecular structure of ALLINI-induced integrase aggregates was not
immediately

obvious.

However,

domain
11

truncations

(Gupta

et

al.

2014),

hydrogen/deuterium exchange (Shkriabai et al. 2014), and molecular modeling (Deng et
al. 2016) implicated the CTD in ALLINI-induced aggregation. Eventually, a molecular
model of the complete integrase-ALLINI complex was determined by our group (Figure
1.3) (Gupta et al. 2016). In this structure, the ALLINI forms extensive contacts with both
the CCD and CTD, linking adjacent dimers of integrase together to form an open
polymer. This polymer differs from the form of integrase observed in the intasome, and is
not expected to be catalytically active. Work is ongoing to determine whether the primary
disruptive effect of this polymer is due to sequestration of integrase from its role in
condensing the viral RNA or physical disruption of the virion (Gupta et al. 2020,
submitted). Although this structure is a dramatic step forward in understanding the
mechanism of action of ALLINIs, it lacks high resolution detail, was determined with a
heavily-modified integrase construct that does not retain catalytic activity, and could only
be achieved with a single ALLINI (Gupta et al. 2016). Addressing these deficiencies is a
major goal of this thesis.
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As with all antiretroviral classes, resistance to ALLINIs is a problem that must be
addressed. Serial viral passage experiments in the presence of ALLINIs has led to the
isolation of multiple resistance mutations (Christ et al. 2010; Tsiang et al. 2012; Christ et
al. 2012; Le Rouzic et al. 2013; Balakrishnan et al. 2013; Sharma et al. 2014; Fader et
al. 2014). Integrase constructs containing resistance substitutions show decreased
aggregation in vitro, supporting a link between a decreased propensity to aggregate and
in vivo resistance. Many resistance substitutions are located at or near the inhibitor
binding site (Gupta et al. 2016), however, some mutations are located distant from the
binding site and convey resistance in yet undiscovered ways. Although some resistance
substitutions are shared between ALLINIs, they do not overlap entirely across different
compounds, emphasizing the importance of characterizing mechanisms of resistance to
enable the development of inhibitors with higher barriers to resistance. Importantly,
identified ALLINI resistance substitutions are non-overlapping with STI resistance
substitutions (Gupta et al. 2016; Tsiang et al. 2012; Blanco et al. 2011), meaning that
ALLINIs offer a complementary approach to existing antiretrovirals targeting integrase.

1.6 Thesis objectives
Structural biology has a proven track record in developing effective antiretrovirals
to combat the HIV epidemic. However, significant challenges and opportunities remain in
the field of HIV research and antiretroviral drug development. In this body of work, I
apply the techniques of structural biology and biochemistry to the task of better
understanding HIV integrase and the antiretrovirals targeting integrase. Reported here is
significant progress toward a better understanding of the function of HIV integrase and
its inhibition by STIs and ALLINIs. In Chapter 2, I extend published data from our lab
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detailing the structural mechanism of action of the ALLINIs. This work improves the
resolution of structural detail, includes additional ALLINIs, elucidates mechanisms of
resistance, and outlines potential routes for compound optimization; progress that will
benefit ongoing drug development. In Chapter 3, I report our collaborative work on a
highly potent ALLINI that emphasizes the promise of this class of compounds. I show
that STI-resistant IN is hypersensitive to this ALLINI, providing a rationale for
combination therapy of STIs and ALLINIs. In Chapter 4, I report the structural,
biochemical, and biophysical characterization of wild type, native HIV-1 integrase. These
data have not been previously reported due to the difficulty of working with HIV-1
integrase in vitro. Our purification approach enabled us to study integrase in the form
found in vivo, and set the foundation for more accurate study of integrase in the future.
Chapter 5 extends the data from Chapter 4, reporting the formation of integrase
complexes with LEDGF and viral DNA. These studies are essential steps toward the
structural determination of the catalytically active integrase·DNA complex, the intasome.
STIs bind to this complex, and determination of its structure with wild type, native HIV-1
integrase is a major future goal. Together, this work advances the understanding of the
complex and multifaceted functions of HIV integrase, and the structures presented here
establish a template for ongoing antiretroviral drug development.
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Chapter 2: Structural details of allosteric HIV integrase inhibitor
binding and resistance
The contents of this chapter are currently being prepared as a manuscript for
publication.
2.1 Abstract
HIV integrase (IN), the enzyme that catalyzes viral integration into genomic DNA,
has been successfully targeted by inhibitors that bind the active site. A second class of
inhibitors, the allosteric integrase inhibitors (ALLINIs), bind a different site and act by a
different mechanism. ALLINIs have not yet been implemented clinically, pending
improvements in specificity, potency, and barriers to resistance—goals that can be
achieved through a better understanding of the structural mechanism of action of
ALLINIs. We have previously co-crystallized full length HIV IN bound with an ALLINI and
reported the structure of this complex. Here, we extend the structural understanding of
ALLINIs through novel IN·ALLINI crystal structures. Two structures of an ALLINI bound
to full-length IN harboring resistance substitutions illustrate possible mechanisms of
ALLINI resistance. These are the first structures of replication-competent full-length IN
bound to an ALLINI, confirming that IN·ALLINI polymers can form in vivo and that
polymer formation is the structural mechanism of action of ALLINIs. A ternary complex
structure of an ALLINI bound to the catalytic core domain and the carboxy-terminal
domain of IN orthogonally confirms the structure of the ALLINI binding site and improves
the resolution of structural detail. Examination of these structures identifies routes for
optimization of existing ALLINI scaffolds.

15

2.2 Introduction
Resistance to antiretrovirals presents a barrier to effective control of HIV and
prevention of transmission, essential goals to end the worldwide HIV epidemic (Clavel
and Hance 2004). Use of potent antiretrovirals with the highest genetic barriers to drug
resistance is essential for minimizing the emergence and spread of resistant virus (B.
Brenner and Wainberg 2016). Antiretrovirals targeting HIV integration, an essential step
in the retroviral replication cycle (Robert Craigie and Bushman 2012), has several
advantages including improved tolerability, fewer side effects or drug-drug interactions,
and, importantly, a high genetic barrier to resistance (Osterholzer and Goldman 2014; M.
M. Miller et al. 2015; B. G. Brenner and Wainberg 2017; Smith et al. 2018; Tsiang et al.
2016; Malet et al. 2018).
The integrase (IN) enzyme is part of the pol gene and cleaved from a polyprotein
precursor by the viral protease. The general structure and three-domain organization of
IN, consisting of the N-terminal domain (NTD), catalytic core domain (CCD), and
C-terminal domain (CTD), is conserved across retroviral families (A. Engelman and
Craigie 1992; A. N. Engelman and Cherepanov 2017; Chiu and Davies 2004; Alan
Engelman and Cherepanov 2014). IN associates with the free ends of viral DNA to form
a macromolecular complex, the intasome, which progresses through three distinct forms
during integration (A. Engelman, Bushman, and Craigie 1993; A. N. Engelman and
Cherepanov 2017; M. D. Miller, Farnet, and Bushman 1997; Lewinski and Bushman
2005; Cook et al. 2020; Passos et al. 2020, 2017; Ballandras-Colas et al. 2017). During
integration, IN catalyzes two sequential reactions: 3’-processing (removal of a GT
dinucleotide from the viral DNA ends) and strand transfer (the covalent insertion of viral

16

DNA ends into host DNA) (Robert Craigie and Bushman 2012). The reaction is likely
completed by host DNA repair enzymes (Yoder and Bushman 2000).
Studies of the enzymatic activity of IN led to the development of the first class of
integrase inhibitors, the strand transfer inhibitors (STIs) (D. J. Hazuda et al. 2000; D.
Hazuda 2012), four of which, raltegravir, elvitegravir, dolutegravir, and bictegravir, have
received FDA approval (Mesplède and Wainberg 2013; A. N. Engelman 2019).
Resistance to STIs is well-documented (You et al. 2016; Malet et al. 2008; I. E. A. Wijting
et al. 2018; I. Wijting et al. 2017; Cooper et al. 2008) and, importantly, different STIs
show overlapping resistance profiles, motivating the search for alternative approaches to
targeting IN (Mesplède and Wainberg 2015; Shimura et al. 2008; Molina et al. 2012;
Garrido et al. 2012).
The allosteric inhibitors of integrase (ALLINIs) were developed as an alternative
approach to targeting IN. ALLINIs bind to a pocket normally occupied by the cellular
cofactor LEDGF/p75 (Christ et al. 2010; Fader et al. 2014; H. Wang et al. 2012; G. Li et
al. 2020). IN associates with the chromatin-associated host factor, LEDGF, which directs
IN toward highly expressed genes (A. R. W. Schröder et al. 2002; Emiliani et al. 2005;
Busschots et al. 2007; Peter Cherepanov et al. 2003; De Rijck et al. 2006; Hombrouck et
al. 2007; G. Maertens et al. 2004; Shun et al. 2007; Vanegas et al. 2005). Integration of
HIV occurs in active transcription units, and knockdown of LEDGF results in a loss of
integration site specificity (Ciuffi et al. 2005; G. P. Wang et al. 2007; Lewinski et al. 2006;
Vandekerckhove et al. 2006) and inhibits HIV replication (Llano, Saenz, et al. 2006). The
LEDGF binding pocket, which is formed by the dimerization of two monomers of IN, was
recognized to be a potential target for drug design (Peter Cherepanov et al. 2005; Christ
and Debyser 2013; Poeschla 2008; Kessl et al. 2009), leading to the development of
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ALLINIs. The major binding interactions are contributed by the pharmacophore
carboxylic acid and tert-butoxy groups with the backbone amides of residues Glu-170
and His-171 and the Thr-174 side chain (Gupta et al. 2014; Tsiang et al. 2012; Le Rouzic
et al. 2013; Christ et al. 2010; Feng et al. 2013; Jurado et al. 2013; Gupta et al. 2016).
The complete molecular structure of the ALLINI binding interface was revealed in a
crystal structure of an IN·ALLINI polymer (Gupta et al. 2016, 2014). The CTD of an
adjacent dimer of IN contributes to ALLINI binding with Tyr-226, Trp-235, Ile-268, and
Lys-266, although the resolution of the currently available structure limits definitive
assignment (Gupta et al. 2016). A major goal of the current study is to improve the
resolution of the ALLINI binding interface.
The major effect of ALLINIs is observed late in the viral replication cycle, after
viral DNA integration into the host cell genome has already occurred (Desimmie et al.
2013; Jurado et al. 2013; Feng et al. 2013; Le Rouzic et al. 2013; van Bel et al. 2014).
ALLINIs interfere with maturation, the process by which a newly budded virion containing
all of the necessary components for infection undergoes proteolytic processing of the
Gag and Gag-Pro-Pol polyproteins, condensing the viral RNA genome and nucleocapsid
into

a

central

ribonucleoprotein

(RNP)

complex

surrounded

by

the

capsid.

ALLINI-treated producer cells produce non-infectious virions containing abnormal,
eccentric electron dense aggregates (Balakrishnan et al. 2013; Gupta et al. 2016, 2014).
These virions contain mislocalized RNP and the eccentric electron dense aggregates
are composed of IN (Jurado et al. 2013; Fontana et al. 2015; Kessl et al. 2016). Studies
using ALLINIs has revealed a role of IN in sequence-specific binding of the viral RNA
genome, suggesting that IN plays an active role in virion maturation (Kessl et al. 2016).
ALLINIs disrupt this role by promoting polymerization of IN (Gupta et al. 2014, 2016;
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Feng et al. 2016; Shkriabai et al. 2014; Deng et al. 2016), by a mechanism similar to that
of the anti-neoplastic drug paclitaxel, which promotes the polymerization of tubulin into
microtubules (Horwitz 1994). It remains unclear whether the effect of ALLINIs on virion
maturation is due to the sequestration of IN into inactive polymers, preventing interaction
with viral RNA and thereby preventing formation of the central RNP complex, or due to
physical disruption of virions by large aggregates of IN. Ongoing work in our group
suggests that IN may be forming a protein gel, a three-dimensional protein aggregate
with specific properties, and thereby disrupting proper virion function (Gupta 2020,
submitted). A secondary effect of ALLINIs is observed early in the viral replication cycle,
and is a manifestation of ALLINIs directly interfering with IN binding to LEDGF (Christ
and Debyser 2013; Christ et al. 2012, 2010; Kessl et al. 2012; Le Rouzic et al. 2013;
Sharma et al. 2014; Tsiang et al. 2012).
The IN construct used to determine the structure of the IN·ALLINI polymer
contained the two substitutions Y15A and F185H, which convey beneficial solution
properties (Gupta et al. 2016; Bujacz et al. 1996; T. M. Jenkins et al. 1995). The F185H
substitution in the CCD mimics the residue present in ASV IN (Bujacz et al. 1996; T. M.
Jenkins et al. 1995), and is replication-competent (A. Engelman et al. 1997). Although
the NTD is not seen in the IN·ALLINI structure, the IN construct used in this crystal
structure contains the substitution Y15A (known to impair replication in vivo) in the NTD
(Takahata et al. 2016). It is therefore important to determine a crystal structure of an
IN·ALLINI polymer with replication-competent IN.
Importantly, ALLINIs target a site on IN distinct from the site targeted by STIs,
and resistance mutations to ALLINIs do not overlap with STI resistance mutations
(Gupta et al. 2016; Blanco et al. 2011; Tsiang et al. 2012), meaning that ALLINIs offer a
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non-redundant approach to targeting IN. ALLINI resistance substitutions can be readily
identified in serial viral passage experiments (Christ et al. 2010; Tsiang et al. 2012;
Christ et al. 2012; Le Rouzic et al. 2013; Balakrishnan et al. 2013; Sharma et al. 2014;
Fader et al. 2014). The mechanisms of several resistance substitutions have been
studied (Feng et al. 2013; Slaughter et al. 2014; Hoyte et al. 2017), albeit with a focus on
the CCD side of the ALLINI binding interface. The vast majority of resistance
substitutions occur in the CCD and would be expected to directly affect ALLINI binding to
the LEDGF binding site, but effects on CCD-CTD interactions in the context of the
complete ALLINI binding interface must be considered (Gupta et al. 2016). We selected
substitutions at Trp-131 and Asn-222 for further structural study as they are distant from
the ALLINI binding interface and do not have an obvious mechanism of resistance. An
understanding of the structural basis for resistance will inform future drug development,
and indirectly, inform our understanding of the solution properties of IN (Gupta et al.
2016; Koneru et al. 2019).
Here, we extend published data from our group showing the structure of an
IN·ALLINI complex, revealing the specific mechanism of action of ALLINIs and making
sense of their primary effect at late stages of the HIV life cycle (Gupta et al. 2016). The
published IN·ALLINI complex structure was determined with an IN construct containing
the Y15A substitution that impairs replication in vivo (Takahata et al. 2016); here, we
report two new structures that are fully replication-competent. These structures include
the substitutions W131C or N222K, which convey resistance to ALLINIs. These
structures show that the IN·ALLINI polymer accommodates replication-competent IN,
and that resistance substitutions do not directly disrupt polymer formation. Instead,
resistance substitutions act by decreasing interaction affinities on the way to polymer
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formation. These structures were determined with the ALLINI BI-D, structurally similar to
the ALLINI GSK1264, used to determine the published IN·ALLINI structure (Gupta et al.
2016), generalizing the structural mechanism of action of these compounds.
Furthermore, we have improved the resolution of structural models of the IN·ALLINI
interface, achieved by separating IN into individual domains and forming a ternary
complex with a ALLINI in vitro. This structure was determined with a third member of the
ALLINI class, BI-224436, and recapitulates the general structure of the IN-ALLINI
interface. From these improved models, routes for improvement to existing ALLINI
scaffolds can be identified, which will be useful for drug optimization in the future.

2.3 Results
2.3.1 Structures of replication competent INs containing resistance substitutions
with the ALLINI BI-D
We sought to improve on our previously published structure of INY15A with the
ALLINI GSK1264 by using replication-competent IN constructs containing ALLINI
resistance substitutions and a different ALLINI, BI-D (Supplemental Figure 2.1)
(Tsantrizos et al. 2009). Substitutions in IN that convey resistance to ALLINIs are
consistently located near the ALLINI binding site, with the vast majority found in the CCD
(Christ et al. 2010; Tsiang et al. 2012; Christ et al. 2012; Le Rouzic et al. 2013;
Balakrishnan et al. 2013; Sharma et al. 2014; Fader et al. 2014). Substitutions that lie
within the binding interface would be expected to prevent ALLINI binding by steric
interactions or disrupting electrostatic or hydrophobic interactions. The mechanism of
resistance of substitutions that lie outside the binding interface is less clear. In serial viral
passage experiments in the presence of ALLINIs, we observed selection for multiple
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resistance substitutions (Gupta et al. 2016). We selected two of these substitutions,
W131C (in the CCD) and N222K (in the CTD) for further structural study (Gupta et al.
2016; Tsiang et al. 2012). Full length IN constructs were purified and crystallized as
reported

previously

(Gupta

et

al.

2016).

Crystals

of

the

two

resistance

substitution-containing IN constructs were grown in the presence of the ALLINI BI-D, and
were in the same space group and diffracted to a similar resolution as the crystals of
INY15A and the ALLINI GSK1264 (Supplemental Figure 2.2). The previously published
INY15A structure (PDB: 5HOT) was used as a search model for molecular replacement.
Crystallographic statistics are found in Table 2.1.
Overall, the structure of the IN constructs with resistance substitutions was the
same as the IN Y15A structure (Gupta et al. 2016) (Figure 2.1a). The ALLINI BI-D binds
at the CCD dimer interface as expected (Jurado et al. 2013; Slaughter et al. 2014).
Residues contributed by the CTD are similar to those observed in the IN Y15A structure,
although the resolution limits definitive assignment of side chain position. The W131C
substitution removes the potential for hydrophobic interactions between Trp-131 and
Ile-268 and cation-π interactions between Trp-131 and Arg-224 (Figure 2.1b). However,
the presence of cysteine at this site allows for the formation of a hydrogen bond with
nearby Tyr-226, which may compensate for the loss of the contributions of Trp-131 to
binding affinity. The N222K substitution also appears to disrupt interactions with Trp-131
on the CCD (Figure 2.1b). Selection for the longer, basic Lys-222 may induce a clash
with Trp-131, decreasing the affinity of the CTD for the CCD. It is also possible that
Lys-222 alters the conformation of the CTD in the absence of CCD binding, through
either a disruption of the CCD-CTD linker or through the formation of a salt bridge
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between Lys-222 and Asp-270. Asp-270 is located near Asn-222 in the solution structure
of the isolated CTD (Lodi et al. 1995; Eijkelenboom et al. 1995, 1999).
Table 2.1: Crystallographic Statistics
Data Collectiona

INW131C, F185H·BI-D

INN222K, F185H·BI-D INCCD·INCTD·BI-224436

P 61 2 2

P 61 2 2

C121

(Å)

104.924
104.924
245.062

106.033
106.033
245.875

90.85
57.756
112.057

(°)

90, 90, 120

90, 90, 120

90, 104.026, 90

Resolution range (Å)

48.23 - 4.56

48.68 - 4.53

27.91 - 2.961

Rmerge

0.1337 (1.664)

0.1402 (2.116)

0.062 (0.709)

CC1/2

99.9 (26.3)

99.7 (30.0)

99.5 (96.1)

Multiplicity

5.4 (4.8)

7.4 (7.7)

4.0 (4.0)

I/σ

6.75 (0.76)

7.06 (1.03)

12.62 (1.73)

Completeness (%)

96.3 (87.53)

99.1 (99.6)

98.23 (95.37)

Reflections (work)

4334

4662

10,574

Reflections (free)

481

517

1159

Rwork

0.332b

0.3017b

0.3484b

Rfree

0.445b

0.4238b

0.4015b

Non-Hydrogen atoms 3276

3289

2784

R.m.s. bonds (Å)

0.042

0.043

0.02

R.m.s. angles (°)

2.78

2.86

1.81

Favored

95.24

94.99

97.29

Allowed

4.26

5.01

2.41

Outliers

0.5

0.0

0.3

Space group
Unit cell dimensions

Refinement

Ramachandran (%)

a

Values in parentheses are for the highest-resolution shell
Refinements utilizing the DEN method implemented in CNS and the Rosetta method
implemented in Phenix are ongoing.
b
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2.3.2 Purification of individual IN domains
As seen in the structure of full-length IN bound with an ALLINI (Figure 2.1,
Supplemental Figure 3a), the ALLINI binding interface is composed entirely of residues
from the CCD and CTD. We therefore truncated IN to remove the NTD, which is not
seen in the full-length IN·ALLINI complex, in an effort to decrease disorder in the crystal
lattice and improve resolution. INCCD and INCTD have previously been purified as
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individual domains and their structures have been determined (Dyda et al. 1994;
Maignan et al. 1998; J. C.-H. Chen et al. 2000; Goldgur et al. 1998; Eijkelenboom et al.
1995, 1999; Lodi et al. 1995). We purified INCCD (residues 50-212) and INCTD (residues
220-271) (Supplemental Figure 3b). INCCD contained the solubility-enhancing substitution
F185K (Dyda et al. 1994). INCTD was truncated at Tyr-271, which is the last residue of the
CTD observed in the full-length IN·ALLINI polymer (PDB: 5HOT) to make contact with
the CCD (Gupta et al. 2016). The remaining residues (272-288) were removed to
decrease disorder in the crystal.

2.3.3 Interaction of INCCD and INCTD in vitro
Addition of ALLINI to full-length IN in vitro results in the formation of a cloudy
precipitate composed of IN oligomers that can be measured by light scattering (Gupta et
al. 2016, 2014, 2010). Surprisingly, addition of ALLINI to an equimolar solution of INCCD
and INCTD also resulted in the formation of a cloudy precipitate (Figure 2.2). This is
unexpected, as full-length IN·ALLINI polymers form by bivalent CCD-ALLINI-CTD
interactions between pairs of IN dimers (Gupta et al. 2016), and the isolated domains
lack the interdomain linker that connects adjacent IN dimers in the full-length IN·ALLINI
polymer (Supplemental Figure 4a). We propose a new model for INCCD and INCTD
oligomer formation whereby INCCD and INCTD form monovalent CCD-ALLINI-CTD
interactions and extend into a polymer by CTD-CTD dimerization (Supplemental Figure
4b). INCTD has been reported to be dimeric in solution (Eijkelenboom et al. 1995; Lodi et
al. 1995), and, as seen in both the NMR (Eijkelenboom et al. 1995) and unpublished
crystal structure of the CTD (PDB: 5TC2), the dimer interface is opposite to the surface
involved in ALLINI binding and is not observed in the structure of full-length IN·ALLINI
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structure (Supplemental Figure 4a). The CTD dimerization interface involves the β2, β3,
and β4 sheets and is predominantly hydrophobic, with significant contributions from
residues Val-240, Leu-242, Trp-243, and Ile-257 (Eijkelenboom et al. 1995, 1999; Lodi et
al. 1995). To test our model of CCD-ALLINI-CTD polymerization, we disrupted the
hydrophobic CTD dimerization interface with the substitution L242A. INCTDL242A was
shown to be dimeric by SEC-MALS and AUC (Gupta 2020, submitted). Mixing of INCCD
and INCTDL242A completely abrogated precipitate formation in the presence of the ALLINIs
BI-224436 and BI-D (Figure 2.2).
2.3.4 Co-crystallization of INCCD, the ALLINI BI-224436, and INCTD
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Mixtures of INCCD, INCTD, and the ALLINI BI-224436 readily crystallized
(Supplemental Figure 2). Crystals could not be replicated in the absence of either
domain or ALLINI. The structure was solved by molecular replacement using the INCCD
dimer (PDB: 3L3U) (Wielens et al. 2010) as a search model. Electron density
corresponding to INCTD and ALLINI was visible, completing the ALLINI binding site as
seen in the full-length IN·ALLINI polymer (Gupta et al. 2016). A dimer of INCCD and 2
monomers of the INCTD could be placed in the asymmetric unit (Figure 2.3a). In
agreement with our model (Supplemental Figure 4b), the crystal lattice revealed open
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polymers consisting of monovalent CCD-ALLINI-CTD interactions and CTD-CTD dimers.
The CTD dimerization interface is rotated approximately 90 degrees from the orientation
observed in solution (Supplemental Figure 4).

2.3.5 Structure of the INCCD·BI-224436·INCTD complex
The overall structure of the IN-ALLINI binding interface is similar to that observed
in the structure of the full-length IN·ALLINI polymer (Gupta et al. 2016). The binding
interface is composed of residues from the ɑ1, ɑ3, ɑ4, and ɑ5 helices of the CCD and
the β1, β1-2 turn, and β5 sheets of the CTD (Figure 2.3b and Figure 2.4). The key
interactions between the BI-224436 pharmacophore and residues Glu-170, His-171, and
Thr-174 are observed. The quinoline scaffold makes contacts with residues Thr-124 and
Thr-125 and approaches Ala-128 (Fader et al. 2014; Koneru et al. 2019). The large
tricyclic arene forms extensive hydrophobic contacts with the CCD (Koneru et al. 2019;
Fader et al. 2014). The interactions with the CTD are primarily hydrophobic and π-π
interactions involving the quinoline scaffold and the tricyclic arene. The quinoline scaffold
projects toward Trp-235 and Tyr-226, and the tricyclic arene contacts Ile-268. Trp-235
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and Tyr-226 adopt the conformation seen in one of two subunits of the IN·ALLINI
polymer determined with GSK1264, with the hydroxyl group of Tyr-226 pointed away
from Trp-235, as seen in the solution NMR structure of the isolated CTD (Lodi et al.
1995) (Supplemental Figure 5). A coordinated flip of these side chains would avoid a
steric clash, and may readily occur in solution. Lys-266 is in a position to participate in
hydrogen bonding with the ALLINI, but adopts a rotamer that projects more toward the
ɑ4-ɑ5 turn of the CCD rather than the ALLINI (Supplemental Figure 5).
Examination of the structures in this study and a high resolution INCCD·BI-224436
structure (Koneru et al. 2019) allowed for the construction of an interaction network and
revealed routes for inhibitor optimization. Two putative hydrogen-bonding networks
bridged by water molecules were identified in the structure (Figure 2.4a). His-171 forms
hydrogen bonds with the tert-butoxy and carboxylic acid moieties and is positioned to
form an interaction with Gln-95 via a water molecule. Similarly, Glu-170 is positioned to
form a hydrogen bond with the aromatic nitrogen in the quinoline ring and Trp-235 via a
water molecule. Expansion of ALLINI scaffolds to displace water molecules and form
additional hydrogen bonds with polar side chains would be expected to improve affinity
and potency of these compounds. Although much of the ALLINI is deeply buried
between the CCD and CTD and solvent-inaccessible, a solvent channel flanked by
Thr-124, Thr-125, and Trp-235 connects the quinoline ALLINI core to bulk solvent.
ALLINI scaffolds could be extended in this direction to form additional contacts with the
CCD and CTD without disrupting existing CCD and CTD contacts.

2.4 Discussion
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The ALLINIs were designed to bind to the LEDGF binding site on the CCD dimer
and exclude LEDGF binding (Peter Cherepanov et al. 2005; Christ and Debyser 2013;
Poeschla 2008; Kessl et al. 2009), inhibiting integration in a similar manner to that of
LEDGF knockdown (Ciuffi et al. 2005; G. P. Wang et al. 2007; Lewinski et al. 2006;
Vandekerckhove et al. 2006; Llano, Saenz, et al. 2006). Surprisingly, the major effect of
ALLINIs occurs late in the viral replication cycle (Desimmie et al. 2013; Jurado et al.
2013; Feng et al. 2013; Le Rouzic et al. 2013) corresponding to a disruption in virion
maturation. This effect is due to polymerization and aggregation of IN. A crystal structure
published by our group revealed the structural mechanism of action of ALLINIs (Gupta et
al. 2016), but was determined with a replication-incompetent IN construct and lacked
high resolution detail. Here, we extend our understanding of ALLINIs with structures of
replication-competent IN constructs containing resistance substitutions with an additional
ALLINI, BI-D. These structures are essential evidence that supports the formation of
IN·ALLINI polymers in vivo and reveal mechanisms of resistance and routes for
optimization of ALLINI compounds. We also report a structure consisting of the two IN
domains involved in ALLINI binding, the CCD and CTD, with an additional ALLINI,
BI-224436. This structure improves the resolution of structural models of the IN-ALLINI
binding interface, further identifying routes for ALLINI compound optimization.
The full-length IN·ALLINI structures reported here harbor the resistance
substitutions W131C or N222K. These structures reveal hydrophobic and electrostatic
disruptions between the CCD and CTD distant from the ALLINI binding site. Instead of
directly interfering with ALLINI binding, these substitutions appear to function by
decreasing the affinity of CCD-CTD interactions. CCD-CTD interactions are not
observed in currently available intasome structures (Passos et al. 2017, 2020), so
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substitutions that decrease the affinity of this interaction would not be expected to affect
IN activity directly. However, ALLINI resistance substitutions have been shown to
decrease fitness in other steps of the viral replication cycle, and are compensated for by
additional substitutions in IN (Hoyte et al. 2017). CCD-CTD interactions are dramatically
strengthened by ALLINIs (Tse et al. 2020), and optimizing ALLINI scaffolds to increase
CCD-CTD affinity would be expected to improve potency. Further study of the spectrum
of resistance substitutions (Christ et al. 2010; Tsiang et al. 2012; Christ et al. 2012; Le
Rouzic et al. 2013; Balakrishnan et al. 2013; Sharma et al. 2014; Fader et al. 2014) is
needed to fully elucidate mechanisms of resistance of ALLINIs and to guide further drug
development.
Before the structure of an IN·ALLINI polymer was determined, indirect evidence
suggested that the CTD contributed to ALLINI binding (Feng et al. 2016; Shkriabai et al.
2014). The structure of the IN·ALLINI polymer clearly confirmed the contribution of the
CTD (Gupta et al. 2016). This CCD-CTD interaction has not been observed in multimeric
IN structures in the absence of ALLINI, although this may be due to the use of
3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS) in vitro (Z. Chen
et al. 2000; E. Deprez et al. 2000). Here, we report a INCCD·BI-224436·INCTD structure
that confirms that the entire ALLINI binding site consists of contributions from both the
CCD and CTD domains. This orthogonal determination of the ALLINI binding interface
shows that it is not a crystallization artifact. The INCCD·BI-224436·INCTD structure
improves the resolution of the structural model of the ALLINI binding site, achieved by
truncating portions of IN thought to be contributing disorder to the IN·ALLINI polymer
crystal structure (the NTD and C-terminal residues in the CTD). The improvement in
resolution will benefit ongoing drug development efforts. Here, we identify two
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hydrogen-bonding networks that involve the ALLINI scaffold and molecules of water.
Modification of existing ALLINI scaffolds to displace these water molecules would be
expected to increase affinity and further stabilize the ALLINI in the CCD-CTD interface.
The major solvent channel connecting to the ALLINI binding pocket represents an
additional avenue of improvement to existing ALLINI scaffolds. Extensions in this
direction from the ALLINI core could form additional interactions with residues on both
the CCD and CTD. Enhancement of CCD-CTD affinity is important to combat drug
resistance from substitutions such as W131C and N222K. As we have shown, IN
constructs containing these substitutions are still capable of forming IN·ALLINI polymers,
but their formation is disfavored by the disruption of hydrophobic and electrostatic
interactions. Enhancement and stabilization of CCD-CTD interactions by expansion of
IN-ALLINI contacts is required.
The previously described CTD-CTD dimerization interface (Eijkelenboom et al.
1995; Lodi et al. 1995) is again observed in the INCCD·BI-224436·INCTD structure. A
molecule of the ALLINI links CCD dimers and CTD dimers together to form an open
polymer in a similar manner to that observed in the full-length IN·ALLINI polymer (Gupta
et al. 2016). In the full-length IN·ALLINI polymer, however, CTD dimers are not
observed, although the dimerization interface is opposite the ALLINI binding interface
and fully accessible. We recently reported that CTD dimerization contributes to
branching of the IN·ALLINI polymer in vitro, leading to the formation of a branched,
gel-like network instead of linear filaments of IN (Gupta 2020, submitted). Residues
involved in CTD dimerization have been shown to be essential for IN oligomerization and
activity (Lutzke and Plasterk 1998), suggesting that the CTD dimerization interface may
be important for uncharacterized oligomeric forms of IN. In the hexadecameric
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maedi-visna virus intasome (Ballandras-Colas et al. 2017), the CTD dimerization
interface mediates interactions between flanking IN subunits, and therefore may be
important in the context of higher-order HIV-1 intasomes (Passos et al. 2017, 2020).
Together, the structures presented here significantly extend published data on
the mechanism of action of ALLINIs and pathways of resistance. Improvements in
resolution identify opportunities to increase potency and raise barriers to resistance, and
use of replication-competent IN connects in vitro data more closely to the retroviral
replication cycle in vivo.
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Chapter 3: Complementary activity of a high-potency ALLINI against
strand transfer inhibitor-resistant integrase
3.1 Abstract
The HIV integrase enzyme is an important target for antiretroviral therapy.
Inhibitors that block strand transfer activity are in widespread clinical use, but resistance
is a significant barrier to durable control. A second class of inhibitors, the allosteric
inhibitors of integrase, offer an alternative approach to targeting integrase. Since
resistance to both classes of inhibitors are non-overlapping, we wondered whether these
two classes could be used for a complementary therapeutic approach. The widely used
strand transfer inhibitor dolutegravir has a high barrier to resistance, but eventually
selects for resistance substitutions in integrase. We tested the susceptibility of these
resistance substitutions to a current-generation, highly potent ALLINI. Integrase
constructs containing dolutegravir-resistant substitutions were more sensitive to the
ALLINI as compared to wild type integrase. However, combination of dolutegravir and
ALLINI did not result in additive or synergistic effects. These data support the
complementary use of strand transfer inhibitors and ALLINIs to combat the development
of resistance.

3.2 Introduction
The identification of the human immunodeficiency virus (HIV) as the causative
agent of the acquired immune deficiency syndrome (AIDS) initiated a tremendous effort
of drug development. Antiretroviral therapy significantly decreased the morbidity and
mortality associated with HIV infection (Palella et al. 1998; Mocroft et al. 1998), and
34

brought the hope of a cure for HIV (Perelson et al. 1997). Unfortunately, HIV remains an
incurable disease despite improvements in lifespan and time to the development of AIDS
(Detels et al. 1998; Schneider et al. 2005; Smit et al. 2006). Major barriers to a cure
remain (Stein, Storcksdieck Genannt Bonsmann, and Streeck 2016), including
antiretroviral drug resistance (Clavel and Hance 2004; Tang and Shafer 2012) and
latency (Pitman et al. 2018). The problem of resistance has been addressed by the
development of multiple classes of antiretroviral drugs targeting nearly every step in viral
replication (Gubernick et al. 2016). The multitude of drug targets results in
non-overlapping resistance to different antiretroviral drug classes. However, resistance
remains a significant cause of treatment failure (Wainberg, Zaharatos, and Brenner
2011; Deeks et al. 2009) and solutions to this problem that do not involve more
complicated (Astuti and Maggiolo 2014; Thompson et al. 2012; Maggiolo et al. 2002) or
toxic (Carr 2003; Willig et al. 2008) regimens are needed.
Antiretrovirals targeting HIV integrase directly address one major barrier to cure:
the establishment of latency. Covalent insertion of the reverse-transcribed viral DNA by
integrase is an essential step in the viral replication cycle, allowing for the transcription of
a new generation of viral RNA and the establishment of latency. Strand transfer
inhibitors (STIs) were developed to directly interfere with integration (Eric Deprez et al.
2004; D. J. Hazuda et al. 2000) by binding to the catalytically active complex of integrase
and viral DNA (Hare, Gupta, et al. 2010; G. N. Maertens, Hare, and Cherepanov 2010;
Hare, Vos, et al. 2010). The STIs have been clinically successful (Demeulemeester, De
Maeyer, and Debyser 2015), and are recommended for first-line regimens (Günthard et
al. 2016; “AIDSinfo” 2019; World Health Organization 2018). However, STIs are
susceptible to another major barrier to cure: the development of resistance (Mesplède,
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Quashie, and Wainberg 2012; Wainberg, Mesplède, and Quashie 2012; Geretti,
Armenia, and Ceccherini-Silberstein 2012; I. E. A. Wijting et al. 2018; You et al. 2016; I.
Wijting et al. 2017). Importantly, resistance to one STI often confers resistance to other
members of the class (D. J. Hazuda, Anthony, et al. 2004; Garrido et al. 2012).
Therefore, the search for other approaches to targeting HIV integrase must continue.
Integrase relies on the host cell cofactor LEDGF for recruitment to chromatin and
integration targeting (Emiliani et al. 2005; Busschots et al. 2007). Knockdown of LEDGF
or overexpression of a dominant negative LEDGF variant inhibited HIV replication
(Llano, Saenz, et al. 2006; De Rijck et al. 2006). The LEDGF-IN interaction was
identified as a potential site for inhibitor development, leading to the development of the
allosteric inhibitors of integrase (ALLINIs) (Christ and Debyser 2013; A. N. Engelman
2019; Poeschla 2008). Although designed to block the LEDGF-IN interaction, important
during the integration step early in the viral replication cycle, the major effect of ALLINIs
is observed late in the replication cycle, after integration has already occurred
(Desimmie et al. 2013; Feng et al. 2013; Le Rouzic et al. 2013; Gupta et al. 2014;
Slaughter et al. 2014). This effect is due to the abnormal multimerization of IN within the
maturing virion, resulting in defective, noninfectious virions (Jurado et al. 2013; Feng et
al. 2013; Desimmie et al. 2013; Le Rouzic et al. 2013; Kessl et al. 2016). The ALLINIs
were found to bridge two domains of IN to form an open polymer, a form distinct from
catalytically active forms of IN (Gupta et al. 2014, 2016).
Together, the STIs and ALLINIs represent complementary approaches to
targeting IN and have non-overlapping resistance profiles (Gupta et al. 2016; Tsiang et
al. 2012; Blanco et al. 2011), making them attractive candidates for combination
antiretroviral regimens. Here, we examine aspects of the combination of the STIs
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raltegravir (Summa et al. 2008) and dolutegravir (Kobayashi et al. 2011) with the ALLINI
ViiV-919 (Peese et al. 2019; G. Li et al. 2020; Sivaprakasam et al. 2020). We show that
ViiV-919 potently inhibits IN strand transfer activity in addition to promoting IN
multimerization. This effect is magnified in the presence of IN substitutions that convey
resistance to STIs, suggesting that resistance to STIs comes at the expense of
increased susceptibility to ALLINIs. These results motivate the investigation of
complementary therapy with STIs and ALLINIs in vivo.

3.3 Results
3.3.1 Aggregation of integrase by the ALLINI ViiV-919
The primary mechanism of action of ALLINIs is the polymerization of IN into
dysfunctional aggregates (Gupta et al. 2016). This activity can be recapitulated in vitro
by the formation of turbid aggregates when IN and ALLINIs are mixed together (Gupta et
al. 2014). The extent of aggregate formation can be measured by the scattering of light
at 405 nm, allowing for the quantification of the ALLINI effect. We measured the effect of
the ALLINIs BI-224436 and ViiV-919 by this method (Figure 3.1). Both ALLINIs induced
the formation of aggregates, but ViiV-919 induced aggregation to a significantly greater
extent compared to BI-224436.

3.3.2 Inhibition of wild type integrase activity by ViiV-919
The ALLINIs do not directly block catalytic activity by binding to the active site. In
vivo, the major effects of ALLINIs is observed late in viral replication, with the integration
step relatively spared from inhibition (Fontana et al. 2015; Balakrishnan et al. 2013;
Sharma et al. 2014). However, in vitro, they do aggregate IN into a form different from
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the canonical intasome (Gupta et al. 2016). Therefore, we tested the effect of the ALLINI
ViiV-919 on the catalytic activity of IN. We first examined inhibition of 3’-processing with
a fluorescence polarization assay (Figure 3.2). The negative control lacking IN enzyme
showed no 3’-processing over time, while the positive control exhibited 3’-processing.
Raltegravir, a strand transfer inhibitor, did not inhibit 3’-processing, as expected. The

38

ALLINI BI-224436 had a minor effect on 3’-processing, while the highly potent ALLINI
ViiV-919 completely inhibited 3’-processing activity.
We next examined the effect of ViiV-919 on strand transfer activity (Figure 3.3).
Strand transfer activity is measured from the integration of a fluorescently-labeled
oligonucleotide into supercoiled plasmid DNA. Single-strand integration events result in
a tagged circle product and concerted (double strand) integration events result in a 2
LTR coupled product. The strand transfer raltegravir and the ALLINI ViiV-919 inhibited
strand transfer activity with similar potency. The IC50 for inhibiting single-strand
integration was 390 nM (95% CI: 334 to 455 nM) and 534 nM (95% CI: 485 to 588 nM)
for raltegravir and ViiV-919, respectively. The IC50 for inhibiting concerted integration was
100 nM (95% CI: 82 to 120 nM) and 106 nM (95% CI: 95 to 117 nM) for raltegravir and
ViiV-919, respectively.

3.3.3 ViiV-919 activity against dolutegravir-resistant integrase
Since we are interested in the utility of combining strand transfer inhibitors and
ALLINIs, we tested whether substitutions that convey resistance to dolutegravir also
conveyed an increased susceptibility to the ALLINI ViiV-919. The substitutions N155H,
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K211R, and E212T were introduced into IN, with and without the polymorphism K156N
(Malet et al. 2018; Koneru et al. 2019). We then examined the effect of ViiV-919 on
3’-processing and strand transfer activity. ViiV-919 completely abrogated 3’-processing
activity in wild type and dolutegravir-resistant constructs (Figure 3.4).

Differences between wild type and dolutegravir-resistant constructs were
observed when examining inhibition of strand transfer (Figure 3.5). The effect on IN
lacking the polymorphism K156N was minimal, with the greatest effect on concerted
integration observed at low concentrations of ViiV-919 (IC25 = 63 nM vs. 30 nM for INwt
and INN155H,

K156N, K211R, E212T

, respectively), and no significant effect on single-strand

integration. However, in the presence of K156N, ViiV-919 more potently inhibited both
single-strand (IC50 = 1.04 µM vs. 103 nM for INwt and INN155H, K156N, K211R, E212T, respectively)
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and concerted integration (IC50 = 138 nM vs. 34 nM for INwt and INN155H, K156N, K211R, E212T,
respectively). Notably, the polymorphism K156N has been implicated as important for
the development of resistance to dolutegravir (Malet et al. 2018). In addition, the
baseline strand transfer activity of the dolutegravir-resistant IN constructs was lower than
wild type IN (Supplemental Figure 3.1), suggesting that dolutegravir resistance arises at
a fitness cost for the virus, a phenomenon also observed to occur in the context of
resistance to ALLINIs (Hoyte et al. 2017) and other antiretroviral drugs (Nijhuis, Deeks,
and Boucher 2001).

3.3.4 Combined activity of raltegravir and ViiV-919
Since both raltegravir and ViiV-919 inhibit strand transfer activity with similar
potency, we next examined whether raltegravir and ViiV-919 showed additive or
synergistic effects on strand transfer activity. We selected a dose of each compound
approximately corresponding to the IC50 of concerted integration (100 nM). As expected,
both raltegravir and ViiV-919 alone inhibited strand transfer to a similar extent (Figure
3.6). The effect on concerted integration was greater than the effect on single strand
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integration, as observed previously (Figure 3.3). Combination treatment with raltegravir
and ViiV-919 at the same doses did not result in additional inhibition, with no evidence of
synergistic or additive activity.

3.4 Discussion
Although antiretroviral therapy has significantly reduced the morbidity and
mortality caused by HIV, the challenges of blocking the establishment of latency and
preventing the development of viral resistance remain. Drugs targeting HIV integrase
directly address these challenges by blocking the enzyme responsible for integration and
exhibiting high barriers to resistance (Tsiang et al. 2016; Naidu et al. 2018; Wiscount et
al. 2008; Métifiot et al. 2011; X. Z. Zhao et al. 2016, 2017; Smith et al. 2018). The strand
transfer inhibitors (STIs) have met with significant clinical success, however, resistance
even to the latest drugs may emerge (I. E. A. Wijting et al. 2018; I. Wijting et al. 2017;
You et al. 2016), motivating the search for complementary approaches to target
integrase. The allosteric inhibitors of integrase (ALLINIs) are a response to this
challenge (A. N. Engelman 2019); their pleiotropic mechanism of action and
non-overlapping resistance profile make them attractive targets for combination with
STIs (Kessl et al. 2012). Here, we report details of this complementary approach.
We show that ViiV-919, a pyrazolopyrimidine ALLINI with an attractive PK profile
(Peese et al. 2019; G. Li et al. 2020; Sivaprakasam et al. 2020), potently aggregates IN.
IN aggregation is the primary mechanism of action of ALLINIs (Kessl et al. 2016; Gupta
et al. 2014, 2016), manifesting late in the viral replication cycle. The structure of the
IN·ALLINI aggregate is distinct from the catalytically active complex (the intasome)
(Gupta et al. 2016), leading us to examine whether the potent ALLINI ViiV-919 also
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inhibited IN activity. We found that ViiV-919 completely abrogated 3’-processing activity,
to a greater extent than the less-potent ALLINI BI-224436, and inhibited strand transfer
activity with a similar potency to the STI raltegravir. These results suggest that potent
inhibition of IN by ALLINIs not only disrupts virion maturation but also inhibits catalytic
activity.
Resistance to STIs is a cause of antiretroviral therapy failure (Wainberg,
Zaharatos, and Brenner 2011; Deeks et al. 2009). Dolutegravir, an STI recommended for
first-line antiretroviral therapy (Günthard et al. 2016; “AIDSinfo” 2019; World Health
Organization 2018), fails to inhibit IN containing the substitutions N155H, K156N,
K211R, and E212T (Malet et al. 2018). We show that IN containing these substitutions
(with or without the K156N polymorphism) can not only be inhibited by ViiV-919, but is
hypersensitive to the ALLINI, highlighting the complementary role of STIs and ALLINIs.
Examination of recent intasome structures suggests a possible basis for hypersensitivity
to ALLINIs (Supplemental Figure 3.2). The N155H and directly adjacent K156N change
likely directly affect Mg2+ and H2O coordination in the active site (Supplemental Figure
3.2a)(Cook et al. 2020), but, importantly, Lys-156 is closely associated with the viral DNA
backbone (Supplemental Figure 3.2b). Substitution of the basic lysine with asparagine
would be expected to negatively affect IN-DNA affinity, potentially destabilizing the
intasome. The K211R and E212T substitutions are located on the helical CCD-CTD
linker, a crucial structure for the formation of the IN·ALLINI polymer (Supplemental
Figure 3.2c). Disruption of this linker through introduction of a proline “kink” or deletion of
Ala-205 conveyed resistance to ALLINIs, but also impaired virus infectivity and
enzymatic activity (Koneru et al. 2019). Further study is needed to determine if
substitutions in this linker convey hypersensitivity to ALLINIs, as seen in this study.
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These investigations should be extended to other STI resistance substitutions to
determine if this is a common theme. Unfortunately, we did not observe additive or
synergistic effects on strand transfer inhibition with the combination of raltegravir and
ViiV-919. A more robust analysis of combination treatment should be carried out in vivo,
where potent inhibition of integration by STIs and the pleiotropic effects of ALLINIs may
result in additive or synergistic effects. The unique mechanism of action of ALLINIs and
their action at both early and late stages of the viral replication cycle make them
attractive candidates for combination with other classes of antiretroviral drugs. In
addition, since antiretroviral therapy regimens involve a combination of several drugs, all
antiretroviral drug candidates must be evaluated for antagonistic effects on other
antiretroviral drug classes. Promisingly, no moderate or strong antagonism has been
observed between the ALLINI BI-224436 and other antiretroviral classes (Fenwick et al.
2014). The ALLINI BI-224436 showed marked synergy with the nucleoside reverse
transcriptase inhibitor (NRTI) tenofovir, but minor antagonism with the NRTI abacavir. IN
and RT are known to interact (Dobard, Briones, and Chow 2007; Tekeste et al. 2015),
and this may be the basis for the interactions observed, but further study is needed to
understand the different effects of two chemotypes from the same class. Moderate
synergy was observed with a selection of protease inhibitors (Fenwick et al. 2014).
ALLINIs have been shown to aggregate the Gag-Pol protein (Desimmie et al. 2013),
which must be accessible for the viral protease to properly initiate virion maturation. Dual
inhibition of Gag-Pol processing by ALLINIs and protease inhibitors may explain the
observed synergy. However, when IN is supplied to virions in trans (by fusion with Vpr),
virions remain fully susceptible to ALLINI inhibition (Liu et al. 1997; Jurado et al. 2013;
Fontana et al. 2015), showing that Gag-Pol may not be the target of ALLINIs. Further
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study will be needed to clarify the synergy between ALLINIs and protease inhibitors.
Combination experiments should be repeated with ALLINIs such as ViiV-919 to identify
opportunities for potent combination.
Viral resistance often arises at a fitness cost for the virus (Hoyte et al. 2017;
Nijhuis, Deeks, and Boucher 2001), and combination antiretroviral therapy should exploit
this fitness defect. These data suggest that STIs and ALLINIs should be combined in
future antiretroviral regimens. Rational combination of complementary antiretroviral
classes will effectively prevent viral integration and prevent the development of
resistance.
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Chapter 4: Influence of the amino-terminal sequence on the structure
and function of HIV integrase
The contents of this chapter have been published:
Eilers, Grant, Kushol Gupta, Audrey Allen, Jeffrey Zhou, Young Hwang, Michael B. Cory,
Frederic D. Bushman, and Gregory Van Duyne. 2020. “Influence of the Amino-Terminal
Sequence on the Structure and Function of HIV Integrase.” Retrovirology 17 (1): 28. doi:
10.1186/s12977-020-00537-x
4.1 Abstract
Antiretroviral therapy (ART) can mitigate the morbidity and mortality caused by
the human immunodeficiency virus (HIV). Successful development of ART can be
accelerated by accurate structural and biochemical data on targets and their responses
to inhibitors. One important ART target, HIV integrase (IN), has historically been studied
in vitro in a modified form adapted to bacterial overexpression, with a methionine or a
longer fusion protein sequence at the N-terminus. In contrast, IN present in viral particles
is produced by proteolytic cleavage of the Pol polyprotein, which leaves a phenylalanine
at the N-terminus (IN 1F). Inspection of available structures suggested that added
residues on the N-terminus might disrupt proper protein folding and formation of
multimeric complexes. We purified HIV-1 IN 1F1–212 and solved its structure at 2.4 Å
resolution, which showed extension of an N-terminal helix compared to the published
structure of IN1–212. Full-length IN 1F showed increased in vitro catalytic activity in assays
of coupled joining of the two viral DNA ends compared to two IN variants containing
additional N-terminal residues. IN 1F was also altered in its sensitivity to inhibitors,
showing decreased sensitivity to the strand-transfer inhibitor raltegravir and increased
sensitivity to allosteric integrase inhibitors. In solution, IN 1F exists as monomers and
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dimers, in contrast to other IN preparations which exist as higher-order oligomers. The
structural, biochemical, and biophysical characterization of IN 1F reveals the
conformation of the native HIV-1 IN N-terminus and accompanying unique biochemical
and biophysical properties. IN 1F thus represents an improved reagent for use in
integration reactions in vitro and the development of antiretroviral agents.
4.2 Introduction
Integration of a reverse-transcribed DNA copy of the HIV RNA genome into a
host cell chromosome is an essential step in retroviral replication (Robert Craigie and
Bushman 2012). The integrated provirus serves as a template for retroviral gene
expression and the production of a new generation of virions. Integration also
establishes the potential for latency, a major barrier to the treatment and cure of HIV-1
infection. Integrase (IN), the retroviral enzyme that catalyzes integration, is produced by
proteolysis of the viral Gag-Pol polyprotein precursor by the virus-encoded protease.
HIV-1 IN is comprised of three domains: the N-terminal (NTD), catalytic core (CCD), and
C-terminal (CTD) domains. Some non-lentiviral INs contain an additional N-terminal
extension domain (X. Li et al. 2011). The NTD adopts a zinc finger fold containing a
conserved HHCC motif essential for activity (Mengli Cai et al. 1997; Zheng, Jenkins, and
Craigie 1996; Z. Zhao et al. 2008). The CCD contains a D,D-35-E motif which binds
divalent metal ions within an RNase H-like fold that comprises the active site (A.
Engelman and Craigie 1992; Kulkosky et al. 1992; Dyda et al. 1994). The CTD adopts
an SH3-like fold and is implicated in DNA binding (J. C.-H. Chen et al. 2000;
Eijkelenboom et al. 1999). Dimers of each isolated domain have been observed (Mengli
Cai et al. 1997; Dyda et al. 1994; Eijkelenboom et al. 1999, 1995; Lodi et al. 1995) and
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recombinant full-length IN has been reported to exist in forms ranging from monomer to
octamer (Hare, Di Nunzio, et al. 2009; A. Engelman, Bushman, and Craigie 1993; Peter
Cherepanov et al. 2003; Faure et al. 2005; McKee et al. 2008; Pandey, Bera, and
Grandgenett 2011).
IN carries out two catalytic reactions: 3’-processing and strand transfer (Robert
Craigie and Bushman 2012), in a macromolecular complex consisting of multiple IN
protomers, viral DNA, cofactors, and host cell proteins termed the intasome (A.
Engelman, Bushman, and Craigie 1993; A. N. Engelman and Cherepanov 2017; M. D.
Miller, Farnet, and Bushman 1997; Lewinski and Bushman 2005; Cook et al. 2020;
Passos et al. 2020, 2017; Ballandras-Colas et al. 2017). Early intasome structures were
determined with IN from the prototype foamy virus (PFV) (Hare, Gupta, et al. 2010;
Hare, Maertens, and Cherepanov 2012; G. N. Maertens, Hare, and Cherepanov 2010;
Yin et al. 2012; Maskell et al. 2015), revealing the structural details of enzymatic activity
and the mechanism of action of the strand-transfer inhibitors (STIs), which displace the
3’ viral DNA end from the active site, rendering the intasome nonfunctional (Cook et al.
2020; Passos et al. 2020; D. J. Hazuda et al. 2000; D. Hazuda 2012). STIs are in
widespread clinical use (Mesplède and Wainberg 2013), however, as with all
antiretrovirals, development of resistance is a major barrier to durable inhibition of viral
replication (You et al. 2016; Mesplède and Wainberg 2015).
PFV intasome structures and homology modeling (B. C. Johnson et al. 2013;
Krishnan et al. 2010) have provided important insight into HIV-1 intasome function;
however, PFV IN diverges significantly from HIV-1 IN in sequence identity, interdomain
linker length, and the presence of an N-terminal extension domain (Peletskaya et al.
2011). Intasome structures from Rous sarcoma virus (RSV) (Yin et al. 2016), mouse
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mammary tumor virus (MMTV) (Ballandras-Colas et al. 2016), and Maedi-visna virus
(MVV) (Ballandras-Colas et al. 2017) have furthered our understanding of HIV-1 IN. In
contrast to PFV IN (Hare, Gupta, et al. 2010; Gupta et al. 2012), study of HIV-1 IN is
challenging due to poor solubility and a propensity to aggregate (Hickman et al. 1994;
Timothy M. Jenkins et al. 1996), along with inefficient catalysis in vitro (Sinha and
Grandgenett 2005; Sinha, Pursley, and Grandgenett 2002; R. Craigie, Fujiwara, and
Bushman 1990; Carteau, Gorelick, and Bushman 1999; Bushman and Craigie 1991;
Kalpana et al. 1994; Goodarzi et al. 1995). Fusion of a small DNA-binding protein,
Sso7d, that mimics the N-terminal extension domain of PFV to the N-terminus of HIV-1
IN improved catalysis and the solubility of HIV-1 intasomes (M. Li et al. 2014), and
enabled structural determination of the HIV-1 core intasome complex by cryo-electron
microscopy (cryo-EM) (Passos et al. 2020, 2017). However, a native HIV-1 intasome
structure remains elusive.
The first N-terminal residue of HIV-1 IN is a highly conserved phenylalanine (B.
Foley et al. 2018; Lightfoote et al. 1986; Steimer et al. 1986) liberated by retroviral
protease cleavage from the C-terminus of reverse transcriptase. Viruses containing
engineered substitutions at IN F1 are replication-incompetent (Lloyd et al. 2007),
showing defects in reverse transcription and integration, characteristic of class II IN
mutations such as those that disrupt the HHCC motif (Leavitt et al. 1996; Masuda et al.
1995; A. Engelman et al. 1995; A. Engelman 1999). Another closely studied NTD
substitution Y15A also affects reverse transcription and integration (Takahata et al.
2016), and INY15A is hypo-oligomeric in solution (Hare, Di Nunzio, et al. 2009; Gupta et al.
2016). Isolated IN NTDY15A is structurally constrained, adopting only one of two NTD
conformational states (the E form) (Nomura, Masuda, and Kawai 2006) while the wild
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type NTD adopts both the E and D forms (Mengli Cai et al. 1997). Conformational
transition between E and D forms involves significant structural rearrangements in the
NTD, including a change in the length of the ɑ1 helix by 6 residues (Mengli Cai et al.
1997). The aberrant phenotypes caused by substitutions at F1 and Y15 led us to
investigate the structure and function of the HIV-1 NTD in more detail.
IN is often produced for laboratory studies by bacterial overexpression in vitro
with an N-terminal methionine (IN MF) (Gupta et al. 2016, 2014, 2010) or as an
N-terminal fusion protein, such as the Sso7d-IN fusion (M. Li et al. 2014; Passos et al.
2017, 2020). Solution structures of the isolated NTD were determined from constructs
purified with a cleavable N-terminal affinity tag (Mengli Cai et al. 1997; M. Cai et al.
1998), so that thrombin cleavage of the fusion protein left three residues (G-S-H-)
preceding F1 (IN GSH). In the solution structure of IN GSHNTD (Mengli Cai et al. 1997),
the backbone carbonyl of F1 contributes the first hydrogen bond of the ɑ1 helix. The
solution structure of another variant, IN GSHNTDH12C, which contains a substitution in the
HHCC Zn-binding motif, shows a different N-terminal structure: the carbonyl of F1 is not
involved in a hydrogen bond, L2 is displaced, and the ɑ1 helix begins with G4 (M. Cai et
al. 1998). The only crystal structure containing the HIV-1 INNTD (PDB: 1K6Y) (J.-Y. Wang
et al. 2001) consists of a two-domain truncated form (NTD-CCD) also purified using an
N-terminal affinity tag and subsequent thrombin cleavage, leaving 3 residues (G-S-H-)
preceding F1 (Timothy M. Jenkins et al. 1996; J.-Y. Wang et al. 2001). In this case as
well, the ɑ1 helix is shortened, suggesting that the extra N-terminal residues might be
disrupting native folding of the ɑ1 helix.
Four NTDs in two structurally distinct positions exist in the HIV-1 core intasome
complex cryo-EM structures determined with Sso7d-IN (Passos et al. 2017, 2020). One
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NTD, positioned close to the viral DNA and the CCD responsible for catalysis, forms
NTD-NTD interactions in the dodecameric HIV-1 intasome and the hexadecameric MVV
intasome (Ballandras-Colas et al. 2017). The ɑ1 helix of this NTD is shortened in the first
HIV-1 tetrameric intasome structure where it begins with Asp 3 (Passos et al. 2017). The
ɑ1 helix is extended in four of five recent intasome structures, with only one structure
showing partial disruption (Passos et al. 2020). The second NTD does not interact with
the viral DNA and is distant from the active site. This NTD does not form NTD-NTD
interactions in dodecameric or hexadecameric intasomes and shows a range of ɑ1
helical structures: disordered, partially unstructured, and extended (Passos et al. 2020).
Intasomes of a closely-related simian immunodeficiency virus were prepared with IN
purified with an N-terminal affinity tag and subsequent human rhinovirus 3C protease
cleavage, leaving 3 residues (G-P-G-) preceding F1 (Cook et al. 2020). The NTDs in
these structures show extended ɑ1 helices.
In this paper, we report a purification scheme of wild type IN with phenylalanine
as the N-terminal residue (IN 1F), and associated alterations in the N-terminal structure
and IN function. IN 1F was purified with an N-terminal affinity tag, which, when removed,
leaves phenylalanine at position 1. We report a two-domain NTD-CCD crystal structure
of IN 1F that shows a continuous helical fold beginning with the backbone carbonyl of
F1, in contrast to the existing IN GSHNTD-CCD structure (J.-Y. Wang et al. 2001). IN 1F also
shows greater concerted integration activity in vitro compared to IN GSH and IN MF. IN
1F is altered in its sensitivity to inhibitors, showing decreased sensitivity to the
strand-transfer inhibitor raltegravir and increased sensitivity to allosteric integrase
inhibitors (ALLINIs). Biophysical characterization reveals that IN 1F has oligomeric
properties distinct from previously studied recombinant IN constructs. We propose that
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HIV-1 IN 1F more closely recapitulates the structure and functions of IN found in
authentic HIV infection.

4.3 Results
4.3.1 Cloning and purification of HIV-1 integrase with a native N-terminus
To determine the biochemical and structural properties of HIV-1 IN with a
phenylalanine at the N-terminus, we cloned NL4-3 IN into an expression vector
containing an N-terminal His7-FLAG-SUMO tag immediately preceding F1. The SUMO
protease Ulp1 cleaves at a G-G-/-X motif (with the cleavage site indicated by /, with X
being any residue except proline) (Mossessova and Lima 2000). This allows for
purification of wild-type IN with a native N-terminus (“IN 1F”) by Ulp1 cleavage at the
sequence G-G-/-F (Supplemental Figure 4.1). To compare to IN with a non-native
N-terminus, we inserted additional N-terminal residues preceding F1. IN GSH contains
the three residues (G-S-H) that remain after thrombin cleavage, as used to determine
the structure of IN GSHNTD-CCD (PDB: 1K6Y)(J.-Y. Wang et al. 2001), and IN MF contains
an

N-terminal

methionine

found

in

constructs

commonly

used for bacterial

overexpression (Gupta et al. 2016, 2014, 2010). A nickel-affinity step captures Ulp1 and
the cleaved affinity tag and subsequent size-exclusion chromatography yields a highly
pure final product (Supplemental Figure 4.1).

4.3.2 Crystallization of an IN 1F NTD-CCD derivative
To investigate structural differences between IN 1F and IN GSH, we created an
IN 1FNTD-CCD construct containing the same solubility-enhancing substitutions (W131D,
F139D, and F185K) used to determine the structure of IN GSHNTD-CCD (J.-Y. Wang et al.
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2001). Affinity purification, Ulp1 cleavage, and size-exclusion chromatography yielded a
highly pure final product (Supplemental Figure 4.1) that readily crystallized as described
previously (J.-Y. Wang et al. 2001). The structure was solved by molecular replacement,
using the existing NTD-CCD structure (PDB: 1K6Y) as a search model. Four copies of
both the NTD and the CCD were present in the asymmetric unit (Figure 4.1a), with the
inter-domain linker (residues 47-55) unresolved in the electron density. In the structure of
IN GSHNTD-CCD, each NTD is assigned to a “distal” position relative to the CCD
(Supplemental Figure 4.2). However, in the crystal structure of the HIV-2 INNTD-CCD
complexed with the lens epithelium derived growth factor (LEDGF) integrase binding
domain (IBD) (PDB: 3F9K) (Hare, Shun, et al. 2009), the interdomain linker is
well-defined in the electron density, placing the NTDs in a “proximal” position relative to
the CCD (Supplemental Figure 4.2). This is also the favored position for the NTDs in
small angle X-ray scattering (SAXS) analysis of IN NTD-CCD coexpressed with the
LEDGF IBD (Gupta et al. 2010). In the IN 1FNTD-CCD structure, the unresolved 10-residue
linker would be long enough to span the unobstructed distance of 28.7-31.8 Å to position
the NTDs in a “proximal” position. We have therefore defined the NTDs in the “proximal”
orientation relative to the CCDs, as observed in the HIV-2 INNTD-CCD structure (Figure
4.1a). Crystallographic statistics are summarized in Table 4.1.
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Table 4.1. Crystallographic Statistics
Data Collection

Overall, (Highest Shell)

Space group

P43211

Unit cell dimensions

102.919 Å x 102.919 Å x 279.203 Å
90°, 90°, 90°

Resolution range (Å)

96.567 - 2.40

Rmerge

0.558 (1.619)

Rp.i.m.

0.110 (0.318)

CC1/2

0.990 (0.289)

Multiplicity

26.6 (26.6)

I/σ

8.1 (1.6)

Completeness (%)

100 (100)

Refinement
Reflections (work)

58492

Reflections (free)

1169

Rwork

22.5%

Rfree

25.3%

Protein atoms

12003

Ligand/ion atoms

28

Water molecules

226

R.m.s. bonds (Å)

0.004

R.m.s. angles (°)

0.589

Ramachandran plot (%)
Favored

98.49

Allowed

1.51

Outliers

0.00

4.3.3 Structure of the IN 1F NTD-CCD construct
The overall structure of IN 1FNTD-CCD is highly similar to IN GSHNTD-CCD (global
RMSD: 0.90 Å). A phosphate ion is found near the active site of each CCD. Each copy
of the NTD folds into a 3-helix motif coordinating a Zn2+ ion with residues H12, H16, C40,
and C43. A potassium ion is coordinated by the carbonyl oxygens of V37, A38, C40,
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C43. Close inspection of the N-terminus reveals differences between IN 1F and IN GSH
(Figure 4.1b). In the asymmetric unit of IN 1F, two secondary structures are observed at
the N-terminus. The ɑ1 helix in chains A and C begins as a hydrogen-bonded turn at the
backbone carbonyl of F1, while in chains B and D, a canonical alpha helix begins at the
backbone carbonyl of F1 (Figure 4.1b, Supplemental Figure 4.3). In IN GSH, the ɑ1 helix
does not begin until D3 due to a shift in the L2 side chain by ~10 Å, accompanied by a
~4.6 Å displacement of the peptide backbone at L2 (Figure 4.1b,c, Supplemental Figure
4.3). F1 is in a similar position in IN 1F and IN GSH, where it caps a hydrophobic core in
the NTD made up of I5, L28, P29, and V32. The N-terminal amino group also differs
between these two structures due to the peptide backbone displacement at L2. In IN
GSH, the N-terminal amino group is oriented toward the C-terminal end of the ɑ2 helix,
whereas in IN 1F, it is flipped ~180° and oriented toward the ɑ3 helix of a neighboring
NTD. The same NTD-NTD interface is observed in dodecameric HIV-1, hexadecameric
MVV, and SIV intasome structures (Cook et al. 2020; Passos et al. 2017, 2020;
Ballandras-Colas et al. 2017), and the NTDs modeled at this position adopt extended ɑ1
helical structures in four of six structures (Supplemental Figure 4.3). The NTDs that do
not form an NTD-NTD interface show a variety of structures: disordered, partially
unstructured, and extended (Supplemental Figure 4.3). Difference maps and simulated
annealing omit maps calculated around the N-terminus of each protomer of the IN
1FNTD-CCD structure confirmed the observed differences between the N-termini of IN 1F
and IN GSH (Figure 4.1d,e).

4.3.4 Activity of IN 1F in vitro
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IN carries out two catalytic functions, 3’-processing and strand transfer, which
can be replicated in vitro using fluorescently-labeled oligonucleotides that mimic the viral
long terminal repeat (LTR). To assay 3’-processing, we used a 3’-fluorescently-labeled
double-stranded oligonucleotide mimicking the viral LTR to monitor release of the
terminal dinucleotide (5’-GT-3’) using fluorescence polarization (Merkel et al. 2009). The
unprocessed oligonucleotide emits highly polarized fluorescence. Upon cleavage by IN,
the released dinucleotide emits fluorescence with low polarization. In the presence of
Mg2+ and Mn2+, IN MF and IN 1F showed similar 3’-processing activities (Figure 4.2).

IN carries out two catalytic functions, 3’-processing and strand transfer, which
can be replicated in vitro using fluorescently-labeled oligonucleotides that mimic the viral
long terminal repeat (LTR). To assay 3’-processing, we used a 3’-fluorescently-labeled
double-stranded oligonucleotide mimicking the viral LTR to monitor release of the
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terminal dinucleotide (5’-GT-3’) using fluorescence polarization (Merkel et al. 2009). The
unprocessed oligonucleotide emits highly polarized fluorescence. Upon cleavage by IN,
the released dinucleotide emits fluorescence with low polarization. In the presence of
Mg2+ and Mn2+, IN 1F, IN GSH, and IN MF showed similar 3’-processing activities (Figure
4.2).
To

assay

strand

transfer

activity,

we

used

5’-fluorescently-labeled

oligonucleotides mimicking the viral LTR and a supercoiled plasmid mimicking
nucleosomal DNA (Figure 4.3a). Concerted integration of two viral LTRs by IN results in
linearization of the supercoiled plasmid and incorporation of the fluorescent label.
Strand-transfer activity in the presence of Mg2+ and Mn2+ was influenced by NaCl
concentration, with the highest level of concerted integration occurring at 150mM NaCl in
the presence of Mg2+ and 200-250mM NaCl in the presence of Mn2+ (Supplemental
Figure 4.4). In identical assay conditions, IN 1F showed superior concerted integration
activity, resulting in the formation of 2 LTR coupled products, as compared to IN GSH
and IN MF at all time points measured (Figure 4.3b,c). This difference was observed in
the presence of either Mg2+ or Mn2+.
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A partial reaction, the integration of a single LTR oligo, results in relaxation of the
supercoiled plasmid and incorporation of the fluorescent label. Quantification of the
fluorescently tagged, relaxed-circular plasmid indicates single-ended integration activity.
Single-end activity, resulting in the formation of tagged circle products, was not improved
by IN 1F as compared to IN GSH or IN MF (Figure 4.3c).
Treatment with the strand transfer inhibitor raltegravir more potently inhibited
both the single-strand and concerted integration activity of IN GSH and IN MF as
compared to IN 1F (Figure 4.3d, Supplemental Figure 4.5). The IC50 for inhibiting
concerted integration was 125 nM (95% CI: 83-186 nM), 109 nM (95% CI: 83-142 nM),
and 370 nM (95% CI: 270-508 nM) for IN GSH, IN MF, IN 1F, respectively. The IC50 for
inhibiting single-strand integration was 253 nM (95% CI: 202-318 nM), 223 nM (95% CI:
141-356 nM), and 1.13 µM (95% CI: 0.73-1.8 µM) for IN GSH, IN MF, and IN 1F,
respectively.

4.3.5 Response of IN 1F and IN MF to ALLINIs
The allosteric inhibitors of integrase (ALLINIs) (Christ et al. 2010; Fader et al.
2014; H. Wang et al. 2012) are a class of small molecule inhibitors that block the
interaction of IN with LEDGF and cause aberrant aggregation of IN (Gupta et al. 2016,
2014; Jurado et al. 2013). ALLINIs aggregate recombinant IN in vitro, causing turbidity
that can be measured by light scattering (Gupta et al. 2016, 2014, 2010). Using this
approach, we measured the sensitivity of IN 1F, IN GSH, and IN MF to ALLINIs (Figure
4.4). ALLINI-induced aggregation is NaCl-dependent, so we tested aggregation at NaCl
concentrations from 250 mM to 1 M. At 1 M NaCl, no aggregation was observed by the
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ALLINIs

BI-224436 (Fader et al. 2014), BI-D (Tsantrizos et al. 2009), or CX04328

(Compound 6 from Christ et al. (Christ et al. 2010)). At NaCl concentrations where
ALLINI-induced aggregation was observed, ALLINIs induced equal or greater
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aggregation of IN 1F as compared to IN GSH or IN MF. BI-224436, BI-D, and CX04328
aggregated IN 1F more than IN GSH at 300-500 mM NaCl, 300-400 mM NaCl, and
300-500 mM NaCl, respectively. Significant ALLINI-induced aggregation of IN GSH was
only observed at 250 mM NaCl, where IN 1F was observed to aggregate in the absence
of ALLINI. BI-224436, BI-D, and CX04328 aggregated IN 1F more than IN MF from
350-500 mM NaCl, 350-400 mM, and 500 mM NaCl, respectively. At lower NaCl
concentrations, ALLINIs induced aggregation of IN 1F and IN MF to an equal extent.

4.3.6 Solution properties of IN with a native N-terminus
One possible explanation for the improved activity of IN 1F is that folding
associated with the native N-terminal sequence changes the oligomerization state. To
investigate this possibility, we analyzed IN 1F and IN MF by size-exclusion
chromatography in line with multi-angle light scattering (SEC-MALS) to determine the
oligomeric state in solution. Both IN 1F and IN MF showed mass profiles consistent with
a monomer-dimer transition (32-64 kD, expected MW of monomer: 32 kD) at eluted
concentrations of ~8-10 µM, as well as retention times consistent with a mixture of
monomers and dimers (Figure 4.5a). Sedimentation velocity analytical ultracentrifugation
(SV-AUC) experiments performed at similar concentrations and temperatures confirmed
the presence of monomers and dimers with the presence of two discrete species at ~2.8
S and ~4 S, respectively (Figure 4.5b). Sedimentation equilibrium analytical
ultracentrifugation (SE-AUC) analysis at 4°C and similar concentrations also confirmed
the presence of monomers and dimers, and global fitting of a monomer-dimer
equilibrium yielded a Kd of 60 ± 6 µM and 127 ± 23 µM for IN 1F and IN MF, respectively
(Figure 4.5c, Table 4.2). An attempt to fit a dimer-tetramer equilibrium could only be
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accomplished with a Kd > 1 mM. Therefore, no evidence of tetramers was observed by
three biophysical methods, in contrast to prior studies performed under similar conditions
with IN expression constructs with an N-terminal methionine (Gupta et al. 2016, 2014,

2010), N-terminal thrombin (Hickman et al. 1994), or human rhinovirus 3C protease
(Hare, Di Nunzio, et al. 2009; Hare, Shun, et al. 2009) cleavage sequences.
Table 4.2: Properties determined by sedimentation equilibrium analysis
Protein

Concentrations
(µM)

Speeds
(krpm)

Model Fita

Massb
(Da)

Kd
(µM)

Global
Reduced χ2

IN 1F

8.9, 14.5

16,20,24

M-D

32330

59.8 ± 6

2.7

IN MF

6.0, 7.9

16,20,24

M-D

32199

126.7 ± 23

1.3

a

M = monomer, D = Dimer
Calculated mass of monomer from sequence

b
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The monomer-dimer behavior of IN 1F in solution also differs from IN with an
N-terminal methionine, C-terminal intein cleavage site, and the solubility-enhancing
substitution F185H, which exists as a mixture of dimers and tetramers in solution (Gupta
et al. 2016, 2010) and is replication-competent in virus (A. Engelman et al. 1997).
Introduction of the F185H substitution into IN 1F (IN 1FF185H) resulted in the formation of
dimers and a spectrum of higher-order aggregates in solution, as determined by
SEC-MALS (Supplemental Figure 4.6). IN 1FF185H retained similar 3’-processing activity
as compared to IN 1F, but showed a significant decrease in single strand and concerted
strand transfer activity (Supplemental Figure 4.6), indicating the effect of the oligomeric
state of IN on strand transfer activity.

4.4 Discussion
In this paper, we report the construction and purification of IN with a native
N-terminus (IN 1F). The crystal structure of IN 1FNTD-CCD reveals an extended ɑ1 helix
starting with F1, as compared to IN GSHNTD-CCD with a shortened helix. Despite the
remainder of the structure showing little to no difference, this change in the N-terminus is
sufficient to improve concerted integration activity. In contrast, the 3’-processing and
single strand integration activities were not affected. We also observed a change in
sensitivity to IN-targeting antiretroviral drugs. IN 1F was less sensitive to the STI
raltegravir and more sensitive to ALLINI-induced aggregation. We suggest that IN 1F will
be useful in studies of IN function and response to inhibitors in the future.
The zinc finger fold of the NTD is shared with other DNA-binding proteins
(Otwinowski et al. 1988; van Pouderoyen et al. 1997; Xu et al. 1995), with residues
homologous to positions 1-3 in IN located adjacent to the phosphate backbone of DNA.
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In retroviral intasomes, the NTD binds to the distal viral DNA ends (A. N. Engelman and
Cherepanov 2017; Passos et al. 2020, 2017; Ballandras-Colas et al. 2017; Hare, Gupta,
et al. 2010; Yin et al. 2016; Ballandras-Colas et al. 2016). However, unlike other
helix-turn-helix binding proteins, the NTD does not insert a helix into the major groove of
DNA, and F1 is distant from the phosphate backbone. The effect of the N-terminal
disruption in IN GSH and IN MF is unclear, because the change is not expected to
disrupt a tetrameric intasome. In the hexadecameric maedi-visna virus intasome,
however, two pairs of NTDs are closely oriented head-to-head (Ballandras-Colas et al.
2017), forming a nearly identical NTD-NTD interface as that observed in the structure of
IN 1F and IN GSHNTD-CCD (J.-Y. Wang et al. 2001). This hydrophobic dimerization
interface would involve significant contributions from F1, in contrast to the dimerization
interface of the isolated NTD which mainly involves the ɑ3 helix (Mengli Cai et al. 1997).
Additional N-terminal residues, such as the N-terminal Sso7d-IN fusion, could induce a
steric clash (Passos et al. 2017). It is possible that such a disruption explains the
presence of heterogeneous, poorly resolved higher-order intasomes reported in the
cryo-EM studies of HIV-1 Sso7d-IN intasomes (Passos et al. 2017, 2020). Additionally,
disruption of the ɑ1 helix could affect binding to LEDGF, as the NTD cooperates with the
CCD in binding LEDGF (Hare, Di Nunzio, et al. 2009; Hare, Shun, et al. 2009).
Destabilization of the intasome and disruption of the IN-LEDGF interaction are possible
explanations for the differences in concerted integration activity and STI sensitivity
between IN 1F, IN GSH, and IN MF.
Surprisingly, we found IN 1F to be more potently aggregated by ALLINIs
compared to IN GSH and IN MF. ALLINIs cause the formation of open polymers of IN
mediated by CCD-CTD interactions (Gupta et al. 2016), and it is not immediately clear
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how addition of N-terminal residues affects this process. Previously, we have shown that
the NTD is dispensable for ALLINI-induced aggregation (Gupta et al. 2014), although
others have reported that constructs lacking the NTD are resistant to ALLINI-induced
aggregation (Koneru et al. 2019), suggesting that the NTD plays a role in modulating
ALLINI-induced aggregation. In multiple structures (Hare, Di Nunzio, et al. 2009; J.-Y.
Wang et al. 2001; Hare, Shun, et al. 2009), the NTD interacts with the CCD in a manner
expected to clash with the CCD-CTD interactions observed in the ALLINI-induced IN
polymer. An effect on competition between the NTD and CTD for CCD binding may
explain the difference in ALLINI potency between IN 1F, IN GSH, and IN MF. Recently,
IN tetramers have been implicated as the preferred target of ALLINIs (Koneru et al.
2019), but we show that IN 1F, which is a mixture of monomers and dimers in solution, is
aggregated by ALLINIs. However, aggregation is NaCl-dependent, and we have not
determined the oligomeric state of IN 1F at lower NaCl concentrations. IN GSH remains
soluble at NaCl concentrations that lead to aggregation of IN 1F in the absence of
ALLINI, demonstrating that additional N-terminal residues can improve solubility. This is
consistent with the observation of improved solubility of Sso7d-IN (M. Li et al. 2014) and
PFV IN, which harbors an N-terminal extension domain (Hare, Gupta, et al. 2010; Gupta
et al. 2012). Additional experiments are needed to determine the details of
ALLINI-induced polymer initiation and propagation.
Wild type IN 1F is a mixture of monomers and dimers in solution, which differs
from previously reported IN preparations containing substitutions at F185 or additional
N-terminal residues which are a mixture of dimers and tetramers (Hare, Di Nunzio, et al.
2009; Timothy M. Jenkins et al. 1996; Gupta et al. 2016, 2010). We found that the
substitution F185H in the IN 1F background resulted in the formation of higher-order
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species in solution. NTD-CCD interactions between residues such as E11 and K186
have been shown to be important for tetramerization (Hare, Di Nunzio, et al. 2009;
Koneru et al. 2019), and we have now shown that modification of the adjacent residue
F185 affects oligomerization in the context of a native N-terminus. Notably, the construct
used to solve the only HIV IN crystal structure with a naturally-occurring F185, HIV-2
INNTD-CCD co-expressed with LEDGF IBD, was dimeric in solution (Hare, Shun, et al.
2009). In this structure, the interdomain linker is clearly resolved in the electron density,
showing that the NTD contacts the CCD in a “proximal” orientation. This is in contrast to
the IN GSHNTD-CCD structure (PDB: 1K6Y) where the interdomain linker is not resolved,
short interdomain linkers are assigned, and each NTD is in a “distal” orientation (J.-Y.
Wang et al. 2001). The interdomain linker is not resolved in our IN 1FNTD-CCD structure,
but we favor longer interdomain linkers, positioning each NTD in a “proximal” orientation,
as this is the orientation observed in the HIV-2 INNTD-CCD-LEDGF co-crystal structure
(Hare, Shun, et al. 2009). Additional work is needed to understand the effect of
substitutions at F185 and K186 on NTD-CCD interactions in dimeric forms of IN.
4.5 Conclusions
HIV IN containing a native N-terminus adopts a distinct structural configuration,
shows improved activity in vitro, and manifests altered sensitivity to inhibitors. Because it
mimics the form of IN produced by proteolytic cleavage in the maturing virion, IN 1F
provides an improved reagent for the study of IN activity in vitro and for use in antiviral
drug development.
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Chapter 5: Characterization of the catalytically active form of
integrase, the intasome
5.1 Abstract
Integrase, the enzyme responsible for the insertion of the HIV genome into a host
cell, is an important target of antiretroviral therapy. The main class of antiretrovirals that
inhibit integrase, the strand transfer inhibitors, target the catalytically active complex
consisting of multiple copies of integrase, the viral DNA, and the host cell DNA, termed
the intasome. The first structures of HIV-1 intasomes have recently been determined,
accomplished by N-terminal fusion of a DNA-binding domain not found in vivo that
increases

activity

and

solubility.

We

recently

reported

the

purification

and

characterization of HIV-1 integrase with a native N-terminus. Here, we report progress
toward the goal of structural, biochemical, and biophysical characterization of the native
HIV-1 intasome. We were able to purify integrase with the host cell co-factor LEDGF,
which improves solubility and activity, and is an important component of intasome
preparations. Using several approaches for intasome preparation, we observe the
formation of intasomes with multiple readouts. These data set the stage for the
structural, biochemical, and biophysical determination of the native HIV-1 intasome, a
significant unmet need in the field.

5.2 Introduction
Integration of a reverse-transcribed DNA copy of the viral RNA genome is an
essential step in the retroviral replication cycle. Integration enables transcription of a new
generation of RNA genomes and subgenomic RNAs encoding viral proteins, as well as
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establishing the potential for latency. Integration is performed by the viral integrase (IN)
through two sequential reactions, 3’-processing and strand transfer (Robert Craigie and
Bushman 2012). In 3’-processing, IN catalyzes the hydrolysis of the viral DNA, releasing
a pair of nucleotides from the invariant CA dinucleotide sequence. The newly exposed
3’-hydroxyl group serves as the nucleophile in attacking a host cell DNA 5’-phosphate,
covalently linking the viral genome to host chromatin (Fujiwara and Mizuuchi 1988;
Brown et al. 1989; A. Engelman, Mizuuchi, and Craigie 1991). Both reactions are
transesterification reactions (Delelis et al. 2008) and are carried out in a nucleoprotein
complex consisting of IN, the viral DNA ends, and associated host cell proteins termed
the intasome (Hare, Maertens, and Cherepanov 2012). One important host cell protein,
LEDGF, has been extensively characterized (Peter Cherepanov et al. 2003; Turlure et al.
2004; Emiliani et al. 2005; G. Maertens et al. 2003). Host cell DNA repair enzymes
subsequently repair the strand breaks and gaps (Brin et al. 2000).
The first structure of a retroviral intasome was determined from the prototype
foamy virus (PFV) using X-ray crystallography (Hare, Gupta, et al. 2010), revealing the
architecture of a tetrameric intasome and the structure of the core intasome complex.
Intasome structures from other retroviral genera have revealed higher-order multimeric
assemblies with a conserved intasome core (Ballandras-Colas et al. 2016; Yin et al.
2016; Ballandras-Colas et al. 2017; Cook et al. 2020), and a series of structures of
reaction intermediates elucidated the sequence of catalysis (Hare, Maertens, and
Cherepanov 2012; G. N. Maertens, Hare, and Cherepanov 2010; Yin et al. 2012).
However, a structure of the clinically important HIV-1 intasome proved difficult to
determine. Advances in cryo-electron microscopy and the creation of an engineered
hyperactive HIV-1 IN construct ultimately enabled the determination of HIV-1 intasome
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structures (M. Li et al. 2014; Passos et al. 2017, 2020). HIV-1 intasome preparations
resulted in a heterogeneous mixture of multiple oligomeric species. The best-resolved
species was tetrameric, like the PFV intasome, which is not surprising, as the
hyperactive HIV-1 IN construct contains an N-terminal fusion domain mimicking the
N-terminal extension domain of PFV IN (M. Li et al. 2014). Higher-order species
including dodecamers and hexadecamers were also observed, raising questions about
the structure of the native HIV-1 intasome. Does native HIV-1 IN adopt multiple
oligomeric intasome forms, and if so, what is the functional relevance of this
conformational heterogeneity? What are the consequences of the non-native N-terminal
fusion? These questions motivate our work to determine the structure of the native HIV-1
intasome.
Additional motivation comes from the fact that millions of people worldwide
depend on antiretroviral therapy to combat the morbidity and mortality of HIV and to
prevent its spread (“UNAIDS Data 2019” 2019). Antiretrovirals targeting the retroviral IN
protein are in widespread clinical use and are part of recommended first-line regimens
(Günthard et al. 2016; “AIDSinfo” 2019; World Health Organization 2018). This clinical
success belies the fact that the structure of the native HIV-1 intasome -- the target of the
strand transfer inhibitors -- remains to be determined. Studies of the conserved intasome
core (Hare, Gupta, et al. 2010; Pandey et al. 2014) have revealed the mechanism of
action of the strand transfer inhibitors, which bind within the two core catalytic sites,
displace the 3’ viral DNA ends, and prevent strand transfer. However, differences
between PFV structures reveals avenues for STI optimization, underscoring the
importance of accurate structure models for drug development
Passos et al. 2020).
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(Cook et al. 2020;

Recently, our group has reported the purification and structural and biochemical
characterization of native HIV-1 IN (IN 1F) for the first time (Eilers et al. 2020).
Importantly, this construct does not contain engineered additional residues at the
N-terminus, and therefore accurately mimics the form of IN present in virions. IN 1F
retains a high level of activity in vitro and has favorable solution properties, making it an
attractive candidate for structure determination, complex formation with host cell
proteins, and intasome preparation. Here, we report progress in complex formation of IN
1F with the host cell protein LEDGF and intasome preparation. IN 1F forms highly pure,
monodisperse, and catalytically active complexes with the host cell protein LEDGF.
Utilizing published approaches of intasome preparation, we show that IN 1F can be
successfully assembled into IN-DNA complexes. These results set the foundation for
future work toward the structural, biochemical, and biophysical characterization of the
native HIV-1 intasome.

5.3 Results
5.3.1 Integrase-LEDGF complex formation
We have previously reported the purification of wild type HIV-1 integrase with a
native N-terminus (IN 1F) (Eilers et al. 2020). Extensive biophysical characterization of
this construct shows that it exists as a monomer-dimer mixture in solution, distinct from
previously characterized IN constructs that exist as higher-order oligomers (Gupta et al.
2014, 2016, 2010; Hickman et al. 1994; Hare, Di Nunzio, et al. 2009; Hare, Shun, et al.
2009). We have extensively characterized IN constructs in complex with LEDGF (Gupta
et al. 2010) which form tetramers. To extend this data, we co-expressed IN 1F with the
LEDGF integrase binding domain (LEDGFIBD), which is known to bind to and stabilize IN
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(McKee et al. 2008; Hare, Di Nunzio, et al. 2009) and has been shown to be important
for intasome formation (Ballandras-Colas et al. 2017; Passos et al. 2017). Initial
experiments were performed without removing the N-terminal affinity tag to evaluate
consistency with previous results. Affinity purification of LEDGFIBD enabled co-purification
of IN 1F and LEDGFIBD (Figure 5.1a). Electrophoretic analysis of this complex revealed
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an apparent stoichiometry of 2:1 IN:LEDGFIBD. Characterization of this complex by size
exclusion chromatography in line with multi-angle light scattering (SEC-MALS) revealed
an absolute molecular mass of approximately 253 kDa, consistent with a tetramer of IN
bound to two molecules of LEDGFIBD (Figure 5.1c,d). A two-domain construct of IN
containing the NTD and CCD (INNTD-CCD) is competent for binding to LEDGFIBD, and has
been previously characterized as a 2:2 INNTD-CCD:LEDGFIBD complex (Gupta et al. 2010).
We successfully isolated a complex of INNTD-CCD (with a retained N-terminal affinity tag)
and LEDGFIBD (Figure 5.1b). Electrophoretic analysis of this complex revealed an
apparent stoichiometry of 1:1, consistent with a 2:2 INNTD-CCD:LEDGFIBD complex.
Although N-terminal modifications do not abrogate IN catalytic activity (M. Li et al.
2014) and allow for the isolation and structural determination of intasome structures
(Passos et al. 2017, 2020), we sought to isolate IN·LEDGFIBD complexes using IN with a
native N-terminus. Ulp1 cleavage of the N-terminal affinity tag of IN 1F liberates an
N-terminal phenylalanine, as found in vivo after proteolytic processing of the pol
polyprotein (Eilers et al. 2020). To accomplish this, we co-expressed IN, LEDGFIBD, and
Ulp1, resulting in cleavage of the affinity tag from IN in vivo. Purification of the complex
was achieved by affinity purification and subsequent cleavage of the LEDGFIBD affinity
tag. We successfully isolated a complex of IN and LEDGFIBD with an apparent
stoichiometry of 2:1 IN:LEDGFIBD (Figure 5.2a). The addition of the detergent
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) was essential for
the solubility of this complex. The same approach was used to isolate a complex of
INNTD-CCD and LEDGFIBD (Figure 5.2b). This complex has an apparent stoichiometry of 2:1
IN:LEDGFIBD, in contrast to the 1:1 stoichiometry of the uncleaved complex (Figure
5.1b).
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5.3.2 Strand transfer activity of Integrase-LEDGF Complexes
IN constructs containing N-terminal modifications have been shown to be
hyperactive in vitro (M. Li et al. 2014). Therefore, we tested the strand transfer activity of
an HFS-IN·LEDGFIBD complex without cleavage of the N-terminal affinity tag (Figure
5.3a). This complex showed both single-strand and concerted integration activity (Figure
5.3b). Single-strand and concerted integration activity were retained after cleavage to
liberate the native N-terminus (Figure 5.3c).
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5.3.3 Intasome preparation
Intasomes of multiple retroviruses have been prepared in vitro (Hare, Gupta, et
al. 2010; Yin et al. 2016; Ballandras-Colas et al. 2016, 2017; Passos et al. 2017, 2020;
Pandey et al. 2014; Cook et al. 2020) through a combination of decreasing the ionic
strength of the buffer and kinetic trapping by blocking catalysis. Catalysis can be blocked
by strand transfer inhibitors (STIs), divalent ions that support assembly but not catalysis
(Ca2+), substitutions in essential active site residues, and artificially stabilized reaction
intermediates. We have utilized each of these techniques in our attempts to prepare
native HIV-1 intasomes. The ultimate goal of intasome preparation is biophysical
characterization and structure determination, which we have not yet accomplished.
Instead, summarized here, is our progress in developing small-scale readouts of
intasome preparation, essential for the determination of optimal preparation conditions
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that can be scaled-up for biophysical analysis, X-ray crystallography, or cryo-electron
microscopy.
As intasome preparation schemes require a decrease in the ionic strength of the
buffer, we first determined the limits of solubility of IN 1F and IN 1F·LEDGFIBD complexes
in the absence of DNA. IN 1F alone was highly susceptible to decreasing ionic strength,
beginning to precipitate spontaneously at NaCl concentrations below 500 mM (Figure
5.4a). The addition of LEDGFIBD significantly improved solubility. IN·LEDGFIBD complexes
began to precipitate below 225 mM (Figure 5.4b). These concentrations were used to
guide subsequent intasome formation experiments. When DNA oligonucleotides
mimicking the viral LTR ends (Supplemental Figure 5.1a) were added to IN·LEDGFIBD
complexes, turbidity decreased, suggesting that the formation of IN·DNA complexes
stabilizes the protein in solution (Figure 5.4c).

Based on these results, we performed small-scale intasome preparations by
dialysis to low ionic strength or direct addition of low ionic strength buffer. Intasomes
were trapped and analyzed with a variety of readouts. The goal is the development of a
small-scale, high-throughput assay to determine optimal conditions. Biophysical and
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structural analysis require large quantities of highly pure complexes, and adjustment of
multiple parameters is required to find the ideal conditions for intasome preparation.

5.3.4 Intasome readout: crosslinking assays
Covalent crosslinking has been used to visualize the formation of intasomes
(Passos et al. 2017; Yin et al. 2016) and crosslinked intasomes may even retain activity
(Faure et al. 2005). We applied the crosslinking technique to intasome preparations by
dialysis to low ionic strength. The DNA template was a mimic of the strand transfer
reaction product, termed the three-way junction (Supplemental Figure 5.1b). This
template mimics the covalently-linked viral DNA and host DNA and is formed by
annealing five separate oligonucleotides (Ren et al. 2007). After dialysis, covalent
crosslinkers were added and resulting products were separated by gel electrophoresis.
Crosslinking with two concentrations of two crosslinkers, disuccinimidyl glutarate (DSG)
and disuccinimidyl suberate (DSS), revealed the presence of higher MW species in the
absence of 3WJ DNA, corresponding to multimers of IN·LEDGFIBD complexes (Figure
5.5). The addition of 3WJ DNA did not result in the formation of distinct higher MW
species, the expected result if intasomes were successfully forming. This result
highlights a major difficulty in intasome readouts: distinguishing between high molecular
weight protein·protein or protein·DNA aggregates and intasomes. We therefore
investigated alternative readouts for intasome formation.

5.3.5 Intasome readout: agarose electrophoretic mobility shift assays
Gel electrophoresis is a commonly used technique for the detection of
protein-nucleic acid interactions (Garner and Revzin 1981; Fried and Crothers 1981),
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and polyacrylamide gels are often preferred over agarose gels for improved resolution
(Hellman and Fried 2007). However, agarose gels are more rapid and less toxic than
polyacrylamide gels and are therefore useful for initial experiments (Chandrasekhar,
Souba, and Abcouwer 1998; Brody et al. 2004; Ream, Lewis, and Lewis 2016). Agarose
electrophoretic mobility shift assays (EMSA) have been used to characterize the
products of intasome preparations (M. Li et al. 2020). We utilized fluorescently-labeled
oligonucleotides mimicking the viral LTRs (Supplemental Figure 5.1c) to assemble
intasomes, which were subjected to agarose gel electrophoresis and detected by
fluorescence imaging. No target DNA was added to enable trapping of intasomes after
assembly. In the absence of IN or the absence of LTR DNA, no high molecular weight
species were observed (Figure 5.6a, lanes 1 and 2). Co-incubation of LTR DNA with
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increasing concentrations of IN resulted in the formation of high molecular weight
species that did not migrate out of the loading well (Figure 5.6a, lanes 3-8). Addition of
LEDGFIBD facilitated the migration of IN·DNA complexes out of the wells in a
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dose-dependent manner (Figure 5.6b, lanes 3-5). The complexes formed a smear in the
gel, possibly due to heterogeneity or poor resolution in the agarose matrix. LEDGF has
been shown to be important for intasome formation (Ballandras-Colas et al. 2017;
Passos et al. 2017), and enhanced migration of IN·DNA complexes in the presence of
LEDGFIBD suggests that it modulates multimerization. When Ca2+ (which allows for
intasome assembly but not catalysis) (Figure 5.6b, lanes 6,7) or the STI raltegravir
(Figure 5.6b, lanes 8,9) were added to IN·DNA·LEDGFIBD complexes, migration was
enhanced further. A discrete but poorly resolved band near the 10 kb marker was
observed, likely representing well-formed intasomes, alongside a highly diffuse smear of
smaller

products,

likely

representing

partial

intasomes

or

non-intasome

IN·DNA·LEDGFIBD complexes (Figure 5.6b, lanes 6-9). Kinetic trapping with Ca2+ (Ellison
and Brown 1994; Ballandras-Colas et al. 2016) and STIs (Pandey et al. 2014; Hare,
Gupta, et al. 2010; Passos et al. 2020; Cook et al. 2020) has been shown to stabilize
intasomes, and their effect on migration observed here further supports this conclusion.
Distinguishing and separating nonspecific IN·DNA complexes from well-formed
intasomes is an essential step in structure determination, so we attempted to
characterize the discrete high molecular weight species in more detail.

5.3.6 Intasome readout: polyacrylamide electrophoretic mobility shift assay
To better resolve the high molecular weight species observed in agarose EMSA,
we utilized polyacrylamide EMSA (native PAGE). IN·LEDGFIBD complexes were dialyzed
to low ionic strength buffer in the presence of 3WJ DNA, then separated on PAGE
without boiling or the addition of Sodium dodecyl sulfate (SDS). A heterogeneous smear
of 3WJ DNA was observed in the absence of IN·LEDGFIBD, and no bands were visible in
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the absence of 3WJ DNA when stained with either a DNA or protein-reactive dye (Figure
5.7a,b). Co-incubation of IN and 3WJ DNA resulted in the appearance of a discrete high
molecular weight band, consistent with intasome formation (Figure 5.7a,b). SDS-PAGE
analysis of the soluble portion of this intasome preparation revealed the presence of
bands corresponding to IN and LEDGFIBD, as expected (Figure 5.7c), showing that both
proteins were involved in intasome formation.

5.3.7 Intasome readout: biophysical techniques
Retroviral intasomes adopt a wide range of oligomeric forms, from tetramers to
hexadecamers (A. N. Engelman and Cherepanov 2017), with different viruses showing
characteristic forms. The oligomeric state of HIV-1 intasomes remains unclear (M. Li et
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al. 2014; Passos et al. 2017, 2020), despite significant effort to determine the oligomeric
state and low-resolution reconstruction of IN subunit arrangements of the native HIV-1
intasome.

Solution

biophysics

approaches

such

as

SEC-MALS or analytical

ultracentrifugation (AUC) can be used to determine the oligomeric state of prepared
intasomes, and subsequent analysis by small-angle X-ray scattering (SAXS) can be
used to generate low-resolution structural models. Unfortunately, our attempts to analyze
intasomes by these approaches have been unsuccessful due to multiple issues. Despite
our efforts to develop high-throughput, small-scale readouts to identify optimal
preparation conditions, native HIV-1 intasomes are still formed with low efficiency.
Additionally, preparations are heterogeneous, with free IN, LEDGFIBD, and DNA
interfering with analysis of intasomes. Distinguishing intasomes from nonspecific IN·DNA
aggregates, especially in a heterogeneous background, is difficult. Small scale, low
concentration intasome preparations are prone to dissociation during analysis.
Stabilization with STIs during dialysis to low ionic strength is infeasible due to the
amount of compound required. Additional work is needed to identify optimal conditions
for intasome formation and stabilization, which can then be scaled-up for biophysical
characterization and subsequent structure determination.

5.4 Discussion
We have recently reported the purification and characterization of wild type,
native HIV-1 IN (IN 1F) (Eilers et al. 2020). This construct is catalytically active and has
favorable solution properties, making it the ideal candidate for complex formation with
host cell proteins, intasome preparation, and structure determination. Here, we report
progress in these areas. IN interacts with multiple host cell proteins (Emig-Agius et al.
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2014), of which LEDGF is the most extensively characterized (Peter Cherepanov et al.
2003; Turlure et al. 2004; Emiliani et al. 2005). LEDGF binds to and stabilizes IN (McKee
et al. 2008; Hare, Di Nunzio, et al. 2009), an interaction that has been shown to be
important for intasome formation (Ballandras-Colas et al. 2017; Passos et al. 2017). We
purified complexes of IN and LEDGF using both full-length IN and INNTD-CCD truncations,
which include the minimal domains involved in LEDGF binding (Peter Cherepanov et al.
2005; Hare, Shun, et al. 2009). These complexes are highly pure and monodisperse,
and full-length IN·LEDGF complexes are fully competent for concerted integration in
vitro. They can be prepared with or without the presence of an N-terminal affinity tag,
useful for additional purification steps either before or after DNA complex formation. The
N-terminal ɑ helix of the IN NTD is opposite the surface that contacts LEDGF, so it is not
surprising that the presence of an affinity tag at the N-terminus does not disrupt complex
formation. Further characterization will be required to determine whether an N-terminal
affinity tag decreases complex stability. In future experiments, a technique for accurately
quantifying IN when present in IN·LEDGFIBD complexes will need to be adopted to
compare activity levels to isolated IN conditions. However, as we have already shown,
IN 1F is hyperactive when compared to IN with N-terminal artifacts (Eilers et al. 2020).
Therefore, we expect that IN·LEDGFIBD complexes are similarly hyperactive.
Successful intasome preparations involve a combination of decreasing buffer
ionic strength (enabling protein-nucleic acid interactions) and kinetic trapping by blocking
catalysis (preventing turnover and disassembly of catalytic complexes) (Hare, Gupta, et
al. 2010; Yin et al. 2016; Ballandras-Colas et al. 2016, 2017; Passos et al. 2017, 2020;
Pandey et al. 2014). IN·LEDGFIBD complexes were stable at near-physiologic ionic
strength, and showed increased solubility in the presence of DNA mimics of the viral
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LTRs. These results suggested the formation of IN·DNA complexes, so we characterized
these complexes through a variety of approaches. Covalent crosslinking revealed the
presence of high molecular weight complexes of IN and LEDGF in the presence or
absence of DNA, with no distinct species observed in the presence of DNA. We are
therefore unable to demonstrate successful formation of intasome complexes by this
technique, but additional investigation with linkers of diverse lengths and chemical
reactivities should be attempted. Electrophoretic mobility shift assays are useful for
detection of protein-DNA interactions (Garner and Revzin 1981; Fried and Crothers
1981), and we utilized two varieties of this approach to analyze intasome preparations:
rapid, low resolution separation by agarose gel electrophoresis and high resolution
separation by polyacrylamide gel electrophoresis. Both techniques revealed the
presence of high molecular weight species consisting of both protein and DNA,
suggestive of intasomes. Unfortunately, detailed characterization of the structure or
oligomeric state of these complexes is not possible by this technique, and our attempts
at further characterization by biophysical approaches (SEC-MALS and AUC) have been
inconclusive. Optimization and scaling-up of preparation methods will enable future
biophysical characterization.
Ultimately, the goal of this work is the determination of the structure and solution
properties of the native HIV-1 intasome. Biophysical characterization and low-resolution
structure determination, such as that obtained by small-angle X-ray scattering, will be a
useful starting point, but high-resolution structure determination by X-ray crystallography
or cryo-electron microscopy is desired. The preliminary work presented here sets the
foundation for these efforts in the future.

85

5.5 Acknowledgments
We thank members of the Van Duyne and Bushman laboratories for advice and
technical assistance. This work was supported by the Penn Center for AIDS Research,
the PennCHOP Microbiome Program, the Johnson Research Foundation, and the
National

Institutes

of

Health

(R61-HL137063,

R01-HL113252,

U19-AI117950,

UM1-AI126620, and T32-AI007632 to F.D.B., R01-AI129661 to F.D.B. and G.V.D.,
P30-AI045008 to F.D.B. and K.G., and R01-NS100081 to K.G.). G.E. was supported by
the NIH Training in HIV Pathogenesis grant (T32-AI007632).

86

Chapter 6: Future Directions and Concluding Remarks

In the studies presented here, we sought to advance the structural, biochemical,
and biophysical understanding of retroviral integrase. HIV remains a global burden on
human health despite the development of highly effective antiretroviral therapy, and
integrase is one of the most important therapeutic targets. Our efforts were focused on
understanding the mechanism of action of, and mechanisms of resistance to, the two
classes of integrase inhibitors, the strand transfer inhibitors (STIs) and the allosteric
inhibitors of integrase (ALLINIs). Our work in Chapter 2 provides a detailed view of the
ALLINI binding interface, essential for the rational design and improvement of ALLINIs.
In future experiments, ALLINI resistance substitutions should be introduced into this
crystal scaffold to obtain higher-resolution structures. Previously, the affinity of ALLINIs
has been determined by displacement of LEDGF (Hou et al. 2008), or indirectly by
measuring aggregation. Separating the CCD and CTD faces of the ALLINI binding
interface allows for dissection of the binding affinity contributions of both domains.
Additionally, the individual domains have much-improved solution characteristics,
enabling the study of binding at physiological conditions. Future work should focus on
further improvements to the resolution of IN·ALLINI structures and a better
understanding of the affinity and kinetics of inhibitor binding.
In Chapter 3, we studied a highly potent ALLINI, ViiV-919, and suggest a
therapeutic niche for the ALLINI compounds in combination with STIs. Compounds in
this class have not progressed beyond phase I clinical trials (Fenwick et al. 2014; Fader
et al. 2014), suggesting insurmountable toxicity. Current generation ALLINIs show a
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more favorable toxicity profile (Peese et al. 2019; G. Li et al. 2020; Sivaprakasam et al.
2020). To motivate ongoing interest in the ALLINIs, future work should identify
opportunities for combinations with clinically successful antiretrovirals. We have shown
that STI-resistant integrase is hypersensitive to ViiV-919, suggesting that the strategic
addition of ALLINIs to a therapeutic regimen may prevent the emergence of resistance.
These studies should be expanded to additional resistance mutations and antiretroviral
classes, and the development of structural models to explain the hypersensitivity of
STI-resistant integrase will allow for rational combinations in the future.
Chapter 4 reports the characterization of wild type, native HIV-1 integrase. This
construct recapitulates the authentic form of integrase found in vivo, and is therefore an
invaluable tool for the study of integrase structure, biochemistry, and biophysics in vitro.
Of particular interest is the structural determination of the HIV-1 intasome, and we
present progress toward this goal in Chapter 5. Methods for intasome preparation,
purification, and structure determination have been detailed in several recent reports,
and are readily applicable to IN 1F (M. Li et al. 2014; Passos et al. 2017;
Ballandras-Colas et al. 2017; Passos et al. 2020; Cook et al. 2020). Intasome structures
determined with IN 1F will have significant immediate impact.
The work in this thesis provides the foundation for future studies aimed at
understanding HIV integrase and improving inhibitors that target this enzyme. It also
highlights the multifaceted role of a single viral enzyme in orchestrating a complex
replication cycle. In the following sections, I will describe areas of ongoing and future
study, with the goal of further understanding HIV integrase structure, biochemistry, and
biophysics.
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6.1 Ternary complex studies - dimerization-deficient, affinity/kinetics, better
resolution crystals
Separate purification of the two domains involved in ALLINI binding, the CCD
and CTD, improved the resolution of structural models of the IN-ALLINI binding interface
(Chapter 2). This approach was successful, in part, due to a reduction in crystal disorder
compared to the full-length IN·ALLINI structure (Gupta et al. 2016). Co-crystallization of
IN and ALLINIs remains difficult, as it competes with unproductive aggregation and
precipitation of IN. We believe that precipitation that occurs in the presence of INCCD,
INCTD, and ALLINI is mediated by CTD-CTD dimerization (Supplemental Figure 2.4), and
have shown a decrease in precipitation when this dimerization interface is mutated. Our
group recently purified a series of dimerization-deficient CTDs (Gupta et al. 2020,
submitted) and showed that they form a ternary complex with CCD and ALLINI that
remains soluble. These ternary complexes are candidates for future crystallization trials.
Additionally, ternary complex formation is unaffected by the presence of an
affinity tag. The affinity tag serves as a “handle” for surface immobilization or fluorescent
labeling, requirements for analysis with interaction techniques such as surface plasmon
resonance (SPR), biolayer interferometry (BLI), or microscale thermophoresis (MST).
The small scale, rapid, and highly sensitive nature of MST is ideally suited to measure
binding affinities of INCCD, INCTD, and ALLINIs. As a proof-of-principle, we have utilized a
fluorophore compatible with MST that binds non-covalently to a polyhistidine affinity tag
(Bartoschik et al. 2018; Sparks and Fratti 2019). Labeling is rapid and does not require
subsequent desalting or cleanup. The high affinity and slow dissociation of such labels
allow for measurements at the low concentrations necessary to determine the affinity
constants of high-affinity ALLINIs.
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Examination of the IN·ALLINI polymer crystal structure suggested that CTD-CTD
dimers could form in solution, leading to unproductive polymer branching and the
formation of insoluble aggregates (Figure 6.1) (Gupta et al. 2020, submitted). We have
also incorporated dimerization-deficient CTD substitutions into full-length IN constructs,
both in the background of IN constructs that crystallized previously in the presence of
ALLINIs (Gupta et al. 2016), and in the background of IN 1F (Eilers et al. 2020). Our aim
is to improve the resolution of IN·ALLINI crystal structures by eliminating the formation of
unproductive CTD-CTD interactions in solution, thereby favoring the formation of
productive crystal contacts. Efforts to purify and crystallize these constructs are ongoing.
A crystal structure with all three domains of IN has yet to be determined, and would
clarify intra- and inter-molecular domain interactions and provide a context for
understanding the complex solution behavior of IN. Future efforts should be directed
toward this goal.
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6.2 Complementarity of STIs and ALLINIs - structural studies of ALLINI resistance
in Intasome
Current antiretroviral development is an especially daunting task. With the
availability of multiple regimens that effectively and durably control HIV replication, new
antiretrovirals must not only show pharmacodynamic potency, but minimal toxicity and
highly favorable pharmacokinetics with long-term bioavailability (Cihlar and Fordyce
2016). Combination of compounds with additive or synergistic effects is a desirable
approach for antiretroviral therapy (Klein et al. 2003; Snyder et al. 2000). ALLINIs and
STIs have been shown to be additive or synergistic against viral replication in vitro
(Fenwick et al. 2014; Christ et al. 2012) as they target multiple steps in the viral
replication cycle, highlighting their potential for combination antiretroviral therapy.
Additionally, ALLINIs retain activity against STI-resistant IN (Christ et al. 2010; Le Rouzic
et al. 2013), and as we show in Chapter 3, may actually show increased potency in this
context. Our data in Chapter 3 should be extended to additional STI-ALLINI
combinations, STI resistance substitutions, and full-cycle replication assays.
We do not yet fully understand the structural basis for ALLINI hypersensitivity in
STI-resistant IN. Recent structures of the intasome offer structural explanations of
complex pathways of STI resistance (Cook et al. 2020; Passos et al. 2020), and these
multimeric assemblies highlight the multitude of intra- and inter-subunit interactions
adopted by IN (Ballandras-Colas et al. 2017; Passos et al. 2017). Reciprocal mapping of
STI resistance substitutions in the context of the IN·ALLINI polymer and ALLINI
resistance substitutions in the context of the intasome will identify potential disruptions
and opportunities for drug design that exploits hypersensitivity. Recent data has begun
to probe the complex interactions in higher-order intasomes (Chivukula et al. 2020),
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highlighting the importance of IN substitutions in intasome formation. Many of these
substitutions, such as those that disrupt the CCD-CTD linker, would also be expected to
affect ALLINI binding. These data highlight the pleiotropic nature of IN substitutions, and
begin to explain how resistance to one class of inhibitors could convey hypersensitivity
to another class. ALLINI and STI resistance substitutions often arise with a tradeoff in
viral fitness, and extensive effort may be necessary to understand the consequences
(Hoyte et al. 2017; Madison et al. 2017). Further investigation in this area will reveal
strategies for improved inhibitor design and rational inhibitor combinations.

6.3 Intasome pursuits
The time between the publication of the first intasome structure from the
prototype foamy virus (Hare, Gupta, et al. 2010; G. N. Maertens, Hare, and Cherepanov
2010) to the publication of the first HIV-1 intasome structure (Passos et al. 2017)
underscores the difficult of studying HIV-1 integrase. Protein engineering and cryo-EM
overcame the difficulties of working with HIV-1 in vitro, enabling structural determination
(M. Li et al. 2014). Additional structures of HIV-1 intasomes and structurally similar
Maedi-Visna

virus

and

simian

immunodeficiency

virus

have

been

published

(Ballandras-Colas et al. 2017; Cook et al. 2020; Passos et al. 2020), but as of the writing
of this thesis, a structure of the native, unengineered HIV-1 intasome has not been
determined. The work in Chapters 4 and 5 describe the purification and characterization
of native HIV-1 integrase, which shows desirable properties in vitro and has yielded
promising results in intasome preparations. This construct should be used in future work
to determine the structure of the native HIV-1 intasome.
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Two major hurdles must be overcome to determine the structure of the native
HIV-1 intasome. The first hurdle is the efficient, reproducible preparation of stable
intasomes. Protocols for intasome preparations for related retroviruses and engineered
HIV-1 integrase constructs are widely available in the literature and are briefly reviewed
in section 5.3.3. Approaches that combine buffer exchange to low ionic strength with
kinetic trapping by Ca2+ or strand transfer inhibitors are likely to be successful, but,
experience has shown that HIV-1 integrase exhibits significantly different behavior in
vitro as compared to the integrases of other retroviruses. Modification of existing
protocols with respect to ionic strength, pH, concentration of protein and DNA, and
additives (e.g. detergents, Zn2+, etc.) will likely be needed. The number of potential
combinations is vast, therefore requiring a readout of successful intasome preparation
that is rapid and compatible with small-scale reactions. A simple turbidity assay is
presented in section 5.3.3, but this is not specific to intasomes as it will also detect
non-specific IN·DNA interactions that affect solubility. Initial experiments with covalent
crosslinking were not successful, but this approach should be pursued further as it is
cost-effective and compatible with small-scale reactions. Agarose and polyacrylamide
gel electrophoretic mobility shift assays (EMSA) are most promising as an intasome
readout as they utilize a small amount of material, can compare multiple conditions
simultaneously, are cost-effective, and can identify discrete, monodisperse species.
EMSA should be used as an initial screening readout, and promising conditions for
intasome preparation should be scaled-up, analyzed by biophysical approaches as
detailed in section 5.3.7, and subjected to structural determination.
A second hurdle exists before structure determination is possible, and this hurdle
will depend on the technique selected. X-ray crystallography and cryo-electron
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microscopy (cryo-EM) have both been used to determine high-resolution intasome
structures. X-ray crystallography requires the growth of crystals, which requires
extensive screening of conditions. Protein-DNA complexes additionally require
experimentation with DNA length and configuration, rapidly multiplying the number of
experiments required. Here we use both short double-stranded oligonucleotides
mimicking the viral LTR ends (Katzman et al. 1989; R. Craigie, Fujiwara, and Bushman
1990) and a more complex mimic of the three-way junction intermediate (Ren et al.
2007). The minimum DNA length for enzymatic activity is well-understood, and long DNA
constructs support activity (P. Cherepanov et al. 1999), so the optimal length for
crystallization will have to be determined empirically. Cryo-EM bypasses the hurdle of
crystallization, but may require additional optimization steps such as the addition of
detergents or the prevention of polymerization (Cook et al. 2020). As shown in section
5.3.2, integrase that retains an N-terminal tag has concerted integration activity and
therefore must be competent to form intasomes. The use of such a tag may be essential
to achieve the purity needed for cryo-EM structural analysis. Through X-ray
crystallography or cryo-EM, successful determination of the structure of the native HIV
intasome will be a high impact contribution to our understanding of the biochemistry of
integrase and mechanisms for its inhibition.
6.4 The uncertain future of ALLINIs
Ten years have passed since the report of the first allosteric integrase inhibitor
(Christ et al. 2010) with no compounds in this class successfully completing clinical
trials. Some compounds have failed clinical development due to existing resistance or
low barriers to resistance (Trivedi et al. 2020). Since the withdrawal of BI-224436 from
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clinical trials, ALLINI development efforts have been directed toward increasing potency
and bypassing viral resistance (Sugiyama et al. 2020; G. Li et al. 2020; Peese et al.
2019). Results from clinical trials of these compounds have not been reported, giving
rise to a pessimistic outlook on the future of ALLINIs.
Recent ALLINIs have favorable stability profiles in vitro (Patel et al. 2020; Peese
et al. 2019) and in model organisms (Sugiyama et al. 2020; G. Li et al. 2020). However,
discordant results between in vitro stability and in vivo pharmacokinetics (G. Li et al.
2020; Peese et al. 2019), as well as significant loss of activity in the presence of human
plasma proteins (Patel et al. 2020; G. Li et al. 2020) highlight the challenges faced in
ALLINI development. In addition, ALLINIs are thought to activate the cytochrome P450
pathway,

potentially

causing

detrimental

drug-drug

interactions.

In one case

(Sivaprakasam et al. 2020), structural modification successfully mitigated the effects on
cytochrome P450, but, as of the publication of this thesis, no compounds from that
publication are currently under investigation in clinical trials. Without a clear
understanding of the pharmacokinetics of ALLINIs in vitro and in model organisms, the
future of this class of compounds is uncertain.
With very few exceptions, ALLINIs consist of a tert-butoxy and carboxylic acid
group attached to an aromatic core that is decorated by a wide variety of chemical
moieties (Supplemental Figure 2.1). Aromatic cores that have been reported are
pyridine,

thiophene,

quinoline,

isoquinoline,

thienopyridine,

pyrazolopyrimidine,

hydro-naphthyridine, and benzene (A. N. Engelman 2019; G. Li et al. 2020; Sugiyama et
al. 2020) (Figure 6.2a). The moieties that decorate this core range from relatively simple
to extremely complex macrocycles, and this chemical space has been thoroughly
explored (A. N. Engelman 2019) (Figure 6.2b). Early ALLINIs included substituents other
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than tert-butoxy and carboxylic acid groups, but the tert-butoxy and carboxylic groups
have become completely invariant in subsequent ALLINI development. It is possible that
the combination of a tert-butoxy and carboxylic acid motif linked to an aromatic core
causes dose-limiting toxicity in humans, and since this portion of the molecule is shared
between otherwise diverse chemotypes of the ALLINI class, diversity must be explored
in this region if the pharmacokinetic properties of ALLINIs are to be optimized.
Abandonment of the ALLINIs without fully exploring chemical diversity would be tragic.

6.5 Concluding Remarks
The work summarized in this thesis represents the focused study of the
structural, biochemical, and biophysical properties of a single viral enzyme. This
enzyme, the retroviral integrase, has proven to be of central importance as a
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pharmaceutical target in the fight against the global HIV pandemic. For this reason
alone, research should continue in earnest beyond the scope of this thesis. Furthermore,
much of this thesis was prepared during the impact of the global coronavirus pandemic,
underscoring the importance of studying the structural, biochemical, and biophysical
properties of viral enzymes. The clinical success of antiretroviral therapeutics targeting
HIV IN should encourage further focused research on viral enzymes. From another
perspective, elucidation of the functions of viral enzymes has provided vast benefits.
Through the study of its three enzymes, protease, reverse transcriptase, and integrase,
HIV has enabled breakthroughs in biochemistry, genetics, gene therapy, clinical
diagnostics, synthetic biology, and countless other aspects of medicine and research. In
Chapter 2, we report advances in our understanding of the ALLINI class of compounds.
The unique mechanism of action of these compounds, which bind within an interface
between molecules of IN, represents a new avenue of drug development (M. Gao and
Skolnick 2012; Glasgow et al. 2019). A molecule which acts in a similar manner, the
anti-neoplastic drug paclitaxel (Horwitz 1994), has been successful clinically. A class of
inhibitors that bind to the HIV capsid (CA) (Singh et al. 2019; Carnes, Sheehan, and
Aiken 2018; Link et al. 2020) bind in a similar manner between two molecules of CA.
Due to their potency, these compounds have the potential to change the paradigm of
HIV treatment, further underscoring the importance of research in this area. Chapter 3
reports our research on a highly optimized member of the ALLINI class and shows the
promise of combinatorial therapy. Further investigation of combinatorial approaches to
therapy will maximize therapeutic effect while minimizing toxicity. Our work detailing the
structural mechanism of action of the ALLINIs and mechanisms of resistance will
advance drug development in this paradigm in the future. Chapter 4 is a major step
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toward accurate in vitro recapitulation of HIV IN. IN 1F will undoubtedly serve as an
important resource for research on HIV in the future. Already, our work in Chapter 5
demonstrates the improvements enabled with the use of IN 1F in the study of the
catalytically active complex of IN with DNA.
Our work could be critiqued for an overly narrow focus on a single enzyme.
However, a dogged effort was required to develop the first class of antiretrovirals
targeting IN, as it was until recently considered to be “undruggable” (Cheng et al. 2007).
Today, antiretrovirals targeting IN are included in recommended first-line regimens and
are some of the most potent compounds with the highest barrier to resistance. Many
years of work were necessary to attain this success, which therefore argues for a
continued narrow focus. Additionally, study of the ALLINIs revealed an essential role of
IN late in the viral replication cycle, and have revealed the pleiotropic functions of other
HIV proteins. Recently, significant progress in structural biology has been achieved
through the use of cryo-electron microscopy. Our future studies will have to extend
beyond X-ray crystallography and adopt this technique to determine the structure of
large IN·protein and IN·DNA complexes. To conclude, this thesis adds to a body of
research and drug development efforts undertaken over the past 30+ years, and
hopefully contributes to the reduction in morbidity and mortality caused by HIV. Falling
victim to its own success, HIV research efforts are shifting elsewhere, and eventually
work will be redirected to different infectious diseases with a greater impact on human
health. However, as this thesis shows, much remains to be discovered through the study
of HIV, and the discoveries so accomplished will be widely applicable to other viruses in
the future.
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APPENDIX
Supporting Information for Chapter 2
Protein Expression and Purification
IN constructs were expressed and purified as described previously (Ciuffi et al.
2006; Diamond and Bushman 2006; Gupta et al. 2010, 2016) (Gupta 2020, submitted).
Briefly, full-length IN and C-terminal domain constructs used for crystallization were
expressed from pET-Duet vectors (Novagen) with C-terminal Mxe intein, chitin binding
domain,

and

polyhistidine

tag.

Gravity

purification

was

performed

through

nickel-nitriloacetic acid (Qiagen) and chitin (New England Biolabs) resins, followed by
intein cleavage activated by 100 mM β-mercaptoethanol. Liberated proteins were
purified through size-exclusion chromatography using a Superdex 75 HiLoad 16/60
column (GE Healthcare) in 20 mM HEPES-NaOH pH 7.5, 1M NaCl, 7 mM CHAPS, 10
µM ZnOAc2, and 10 mM dithiothreitol (DTT).
Individual IN domains (CCD constructs for both crystallization and aggregation
assays and CTD constructs for aggregation assays) were inserted into an expression
vector containing an N-terminal His7-Flag-Sumo tag (Eilers et al. 2020) (Gupta 2020,
submitted). Proteins were purified with nickel-nitriloacetic acid resin, and either subjected
to

size-exclusion

chromatography

(for

aggregation

assays)

or

a

second

nickel-nitriloacetic column after fusion proteins were liberated by cleavage with Ulp1.
CCD constructs were purified through size-exclusion chromatography using a Superdex
75 HiLoad 16/60 column (GE Healthcare) in 20 mM HEPES-NaOH pH 7.5, 300 mM
NaCl, and 2 mM DTT.
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Purified proteins were concentrated in an Amicon Ultra-15 (Millipore), flash
frozen with 10% glycerol, and stored at -80°C.
Site-directed mutagenesis (QuikChange, Stratagene) was used to generate point
mutations (W131C, N222K, L242A) used in this study.

Crystallization and structure determination
Full-length IN constructs containing resistance substitutions were crystallized as
previously published (Gupta et al. 2016). The ALLINI BI-D (Fader et al. 2014) was
purchased from MedChemExpress (Monmouth Junction, NJ, U.S.A.), resuspended in
1,3-dimethyl-2-imidazolidinone (DMI, Fluka), and was present at a final concentration of
1 mM for crystallization. IN was mixed 1:1 with a solution containing 30% 2-methyl-2,4
pentanediol (MPD), and 0.1 M sodium citrate pH 5.6 in standard hanging drop format at
21°C. Crystals appeared after 24-48 hours and grew to maximal size within one week.
Crystals were harvested and frozen directly from hanging drops. Diffraction data was
collected at the 24-ID-E beamline of the Advanced Photon Source (Argonne National
Laboratory).
Data reduction was performed using XDS (Kabsch 2010). Molecular replacement
and refinement were carried out in Phenix (Liebschner et al. 2019; Adams et al. 2010)
and CNS (Brunger 2007; Brünger et al. 1998). The structures were solved using 5HOT
as a search model (Gupta et al. 2016). The asymmetric unit contained a dimer of IN and
two ALLINI molecules. Manual building and refinement were carried out in COOT
(Emsley et al. 2010). Later rounds of refinement utilized the DEN method (Brunger,
Adams, et al. 2012; Brunger, Das, et al. 2012; G. F. Schröder, Levitt, and Brunger 2014)
with high-resolution structures of INCCD (Gupta et al. 2014) and INCTD (Z. Chen et al.
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2000) as reference models and the Rosetta method as implemented in Phenix (DiMaio
et al. 2013). Figures were created with PyMOL (DeLano 2004).
INCCD, INCTD, and BI-224436 were crystallized by mixing 100 µM INCCD, 100 µM
INCTD, and 500 µM BI-224436 in 20 mM Tris pH 7.4, 250-300 mM NaCl, and 1 mM DTT
with 25% ethylene glycol. The ALLINI BI-224436 (Fenwick et al. 2014) was purchased
from MedChemExpress (Monmouth Junction, NJ, U.S.A.) and resuspended in
acetonitrile. Crystals also grew in 0.2 M magnesium formate, but diffracted poorly.
Addition of 100 µM ammonium acetate improved crystal growth and yielded large single
crystals > 200 µm in length within one week. Crystals were harvested and frozen directly
from hanging drops. Diffraction data was collected at the 17-ID-1 (AMX) beamline at the
National Synchrotron Light Source II (Brookhaven National Laboratory).
Data reduction was performed using DIALS (Winter et al. 2018). Molecular
replacement and refinement was carried out in Phenix (Liebschner et al. 2019; Adams et
al. 2010) and COOT (Emsley et al. 2010). A partial solution was determined using the
INCCD dimer (PDB: 3L3U) (Wielens et al. 2010) as a search model. The INCTD (PDB:
1IHV) (Lodi et al. 1995) could be placed with a subsequent search. A dimer of INCCD, two
molecules of the ALLINI, and two copies of INCTD occupy the asymmetric unit. Initial
steps of refinement included INCCD and INCTD reference models and NCS restraints. Later
steps utilized the Rosetta method as implemented in Phenix (DiMaio et al. 2013).

Aggregation assay for ALLINIs
Assays were performed as previously described (Gupta et al. 2014, 2016) in a
plate reader (Victor 3V, Perkin Elmer), measuring the turbidity of the reaction solution at
405 nm. Final reaction conditions were 20 mM HEPES, pH 7.5, 15 μM IN, 175 mM NaCl,
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1.2 mM CHAPS, and 30 μM ALLINI. Significance was evaluated by two-way ANOVA
with P values reported from Tukey’s multiple comparisons test.
Supplemental Figures
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Supporting Information for Chapter 3
Protein expression and purification
IN constructs were expressed as previously described (Gupta et al. 2016, 2010;
Ciuffi et al. 2006; Diamond and Bushman 2005, 2006; Eilers et al. 2020). Briefly,
expression constructs were introduced into E. coli BL21(DE3), grown in 2xYT at 37°C to
an optical density of 1.8-2.2, and induced by isopropyl-β-D-1-thiogalactopyranoside
(IPTG). Expression was allowed to continue for 5 hours at 20°C before pelleting and
storage at -80°C.
Full-length IN 1F was purified as previously described (Eilers et al. 2020) by
separation on a nickel-nitrilotriacetic acid resin column (Qiagen), cleavage with Ulp1 to
liberate the His7-Flag-Sumo tag, separation on a second nickel-nitrilotriacetic acid resin
column, and size-exclusion chromatography using a Superdex 75 HiLoad 16/60 column
(GE Healthcare). IN was concentrated at 4°C in an Amicon Ultra-15 (Millipore), glycerol
was added to a final concentration of 10% (w/v), and aliquots were flash-frozen in liquid
nitrogen for storage at -80°C.
LEDGFIBD (Ciuffi et al. 2006) was purified as previously described (Eilers et al.
2020).

Small molecule inhibitors
BI-224436 was purchased from MedChemExpress, ViiV-919 was provided by
ViiV Healthcare, and raltegravir was a gift from Merck. Inhibitors were resuspended in
DMSO.

Aggregation assay for ALLINIs
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Assays were performed as previously described (Gupta et al. 2014, 2016; Eilers
et al. 2020). Reaction conditions included 20 mM HEPES-NaOH pH 7.5, 15 μM IN, 300
mM NaCl, 7 mM CHAPS, and 30 μM ALLINI. Turbidity was measured at one-minute
intervals in a plate reader (Victor 3V, Perkin Elmer) as the absorbance of the reaction
solution at 405 nm. Data plotted are the maximum absorbance values reached during a
15 minute assay. Significance was evaluated by one-way ANOVA with P values reported
from Tukey’s multiple comparisons test. Data analysis was carried out in Prism
(GraphPad).

Integrase 3’-processing assay
Assays were performed as previously described (Merkel et al. 2009; Guiot et al.
2006; Eilers et al. 2020). Final assay conditions were 400 nM IN with 20 mM
HEPES-NaOH pH 7.5, 100 nM Alexafluor 488-labeled LTR substrate, 50 mM NaCl, 10
mM MgCl2, 10 μM Zn(OAc)2, 10 mM DTT, and 5 μM inhibitor. Reactions were incubated
at 37°C and stopped by addition of SDS to a final concentration of 0.25%. After 15
minutes, fluorescence polarization was analyzed with a plate reader (Victor 3V, Perkin
Elmer). Significance was evaluated by one-way ANOVA with P values reported from
Tukey’s multiple comparisons test. Data analysis was carried out in Prism (GraphPad).

Integrase strand transfer assay
Assays were performed as previously described (Bushman, Fujiwara, and
Craigie 1990; Bushman and Craigie 1991; K. Gao, Butler, and Bushman 2001; Gupta et
al. 2016; Eilers et al. 2020). Final assay conditions were 3 μM IN, 20 mM HEPES-NaOH
pH 7.5, 0.5 μM Alexafluor 488-labeled LTR substrate, 0.5 μM LEDGFIBD, 150 mM NaCl,
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10 mM MgCl2, and 10 μM Zn(OAc)2. Inhibitors were added from 10x stocks in DMSO to
final concentrations as specified in the text. After 30 minutes at 37°C, pUC19 was added
to a final concentration of 15 nM. Reactions were incubated for 1 hr at 37°C, then
quenched by addition of 0.5% SDS, 15 mM EDTA, and 1 mg/mL proteinase K. Products
were analyzed on 1.5% agarose gels and quantified by ImageJ. Data analysis was
carried out in Prism (GraphPad). Dose-response curve fits used a four-parameter logistic
regression with a variable Hill slope. Significance was evaluated by one-way ANOVA
with P values reported from Tukey’s multiple comparisons test. Data analysis was
carried out in Prism (GraphPad).

Supplemental Figures
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Supporting Information for Chapter 4
Construction of IN expression vectors
The NL4-3 HIV-1 IN coding sequence was amplified by PCR, fused to an
N-His7-Flag-Sumo tag using 4-primer PCR, and cloned into a pCDFDuet expression
vector. The fusion junction contains the sequence “G-G-F”, where cleavage by the
SUMO protease Ulp1 occurs after the second glycine, liberating IN with a phenylalanine
at position 1. IN GSH and IN MF were created by insertion of additional codons
preceding the native phenylalanine by inverse PCR (IN GSH) or site-directed
mutagenesis (IN MF). IN 1FNTD-CCDF185K,

W131D, F139D

was constructed by truncation of the

full-length construct and insertion of a synthetic cassette containing the amino acid
substitutions. The lens epithelium derived growth factor (LEDGF) integrase binding
domain (IBD) (residues 347-471) was cloned into a pETDuet expression vector with the
Mxe intein, a chitin binding domain, and a His6 tag as previously described (Ciuffi et al.
2006).

Protein expression and purification
IN constructs were expressed as previously described with some modification
(Gupta et al. 2016, 2010; Ciuffi et al. 2006; Diamond and Bushman 2005, 2006).
Expression plasmids were transformed into E. coli BL21(DE3) and grown in 800mL of
2xYT at 37°C to an optical density of 1.8-2.2. Expression was induced by addition of
isopropyl-β-D-1-thiogalactopyranoside (IPTG) and allowed to continue for 5 hours at
20°C. Bacteria were then pelleted and frozen at -80°C.
Full-length IN constructs were purified as described previously (Gupta et al.
2010; Ciuffi et al. 2006; Diamond and Bushman 2006). Briefly, lysates were loaded onto
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nickel-nitrilotriacetic acid resin (Qiagen). Fusion proteins were eluted with 20 mM
HEPES-NaOH

pH

7.5,

1

M

NaCl,

7

mM

3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 10 µM ZnOAc2,
5 mM β-mercaptoethanol, and 250 mM imidazole. Fusion proteins were liberated from IN
by overnight cleavage with the SUMO protease Ulp1 (Life Sensors) at 4°C, with
simultaneous dialysis against 20 mM HEPES-NaOH pH 7.5, 1 M NaCl, 7 mM CHAPS,
10 µM ZnOAc2, and 5 mM β-mercaptoethanol. The affinity tag was separated from IN by
a second nickel-nitrilotriacetic acid purification step and further purified using a Superdex
75 HiLoad 16/60 column (GE Healthcare) at room temperature, eluted isocratically in 20
mM HEPES-NaOH pH 7.5, 1 M NaCl, 7 mM CHAPS, 10 µM ZnOAc2, and 2 mM
dithiothreitol (DTT). IN 1FNTD-CCDF185K,

W131D, F139D

was lysed in 50 mM sodium/potassium

phosphate pH 7.0, 500 mM NaCl, 2 mM β-mercaptoethanol, and 10 mM imidazole,
loaded onto nickel-nitrilotriacetic acid resin, and eluted with 50 mM sodium/potassium
phosphate pH 7.0, 500 mM NaCl, 2 mM β-mercaptoethanol, and 250 mM imidazole. The
affinity tag was liberated from IN by overnight cleavage with the SUMO protease Ulp1,
with simultaneous dialysis against 20 mM sodium/potassium phosphate pH 7.0, 500 mM
NaCl, and β-mercaptoethanol. The affinity tag was separated from IN by a second
nickel-nitrilotriacetic acid purification step and further purified using a Superdex 75
HiLoad 16/60 column (GE Healthcare) at room temperature, eluted isocratically in 20
mM HEPES-NaOH pH 7.5, 500 mM NaCl, and 2 mM β-mercaptoethanol. IN was
concentrated at 4°C in an Amicon Ultra-15 (Millipore), glycerol was added to a final
concentration of 10% (w/v), and aliquots were flash-frozen in liquid nitrogen for storage
at -80°C.
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LEDGF IBD was purified using nickel-nitrilotriacetic acid (Qiagen) and chitin
(New England Biolabs) resins. After fusion proteins were liberated by intein cleavage in
50 mM DTT overnight at 4°C, LEDGF IBD preparations were further purified using a
Superdex 75 HiLoad 16/60 column (GE Healthcare) at room temperature, eluted
isocratically in 20 mM HEPES-NaOH pH 7.0, 1 M NaCl, 7 mM CHAPS, 10 µM ZnOAc2,
and 10 mM β-mercaptoethanol. The LEDGF IBD was concentrated at 4°C in an Amicon
Ultra-15 (Millipore), glycerol was added to a final concentration of 10% (w/v), and
aliquots were flash-frozen in liquid nitrogen for storage at -80°C.

Crystallization and structure determination
Crystals were grown by vapor diffusion as previously described (J.-Y. Wang et al.
2001). Briefly, 4 μL of protein at 5-10 mg/mL in 0.5 M NaCl, 20 mM HEPES pH 7.5, 100
µM ZnCl2, 5% (w/v) glycerol, and 5 mM DTT was mixed with 4 μL of reservoir solution
containing 0.7 M NaH2PO4, 1.0 M K2HPO4 and 0.1 M acetate pH 4.6. Two crystal forms
were observed, flat hexagons and long tetragonal crystals, with only the latter exhibiting
high resolution diffraction. Crystals were cryo-protected in 0.8 M NaH2PO4, 1.2 M
K2HPO4, 0.2 M NaCl, and 20% glycerol and flash-frozen in liquid nitrogen. Diffraction
data was collected at 100 K using an Eiger 9M pixel-array detector on beamline 17-ID-1
(AMX) at Brookhaven National Laboratory (M. S. Miller et al. 2019; Fuchs et al. 2016).
Diffraction data were reduced with DIALS (Winter et al. 2018). Molecular
replacement, refinement, and the generation of simulated annealing omit maps were
carried out in Phenix (Liebschner et al. 2019). The structure was solved by molecular
replacement using 1K6Y as a search model. The asymmetric unit contained four
monomers (each containing a Zn2+, K+, and phosphate ion) and 226 waters. The
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structure was refined to a R and Rfree of 22.5% and 25.3%, respectively. Molecular
models were visualized with PyMOL (Schrödinger 2015) and secondary structure was
analyzed with Define Secondary Structure of Proteins (DSSP) (Touw et al. 2015; Kabsch
and Sander 1983).

Integrase 3’-processing assay
The 3’-processing assay was adapted from those described previously (Merkel et
al. 2009; Guiot et al. 2006). HIV integrase at 60 μM in 20 mM HEPES-NaOH pH 7.5, 1 M
NaCl, 7 mM CHAPS, 10 mM DTT, and 10 μM Zn(OAc)2 was diluted to a final assay
concentration of 400 nM with 20 mM HEPES-NaOH pH 7.5, 100 nM Alexafluor
488-labeled LTR substrate, 50 mM NaCl, 10 mM MgCl2 or MnCl2, 10 μM Zn(OAc)2, and
10 mM DTT. Final assay conditions were identical for IN 1F, IN GSH, and IN MF.
Unprocessed U5 LTR substrates with a 3’ Alexafluor 488 N-hydroxysuccinimide (NHS)
ester label were prepared by annealing the following oligonucleotides (Integrated DNA
Technologies):
●

5′-ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGT-Alexa488-3′

●

5’-ACTGCTAGAGATTTTCCACACTGACTAAAAGGGT-3’

Reactions were incubated at 37°C. SDS was added to a final concentration of 0.25% to
stop the reaction and liberate cleaved dinucleotide. After 15 minutes, fluorescence
polarization was analyzed with a plate reader (Victor 3V, Perkin Elmer). Significance was
evaluated by two-way ANOVA with P values reported from Tukey’s multiple comparisons
test. Data analysis was carried out in Prism (GraphPad).

Integrase strand transfer assay
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The strand-transfer assay was adapted from those described previously
(Bushman and Craigie 1991; Gupta et al. 2016; K. Gao, Butler, and Bushman 2001;
Bushman, Fujiwara, and Craigie 1990). HIV integrase at 60 μM in 20 mM HEPES-NaOH
pH 7.5, 1 M NaCl, 7 mM CHAPS, 10 mM DTT, and 10 μM Zn(OAc)2 was diluted to a final
assay concentration of 3 μM with 20 mM HEPES-NaOH pH 7.5, 0.5 μM Alexafluor
488-labeled LTR substrate, 0.5 μM LEDGF IBD, 50-250 mM NaCl, 10 mM MgCl2 or
MnCl2, and 10 μM Zn(OAc)2. Final assay conditions were identical for IN 1F, IN GSH,
and IN MF. Processed U5 LTR substrates with a 5′ Alexafluor 488 N-hydroxysuccinimide
(NHS) ester label were prepared by annealing the following oligonucleotides (Integrated
DNA Technologies):
●

5′-Alexa488-ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3′

●

5’-ACTGCTAGAGATTTTCCACACTGACTAAAAGGGT-3’

After 30 minutes at 37°C, 15 nM pUC19 plasmid was added. Reactions were carried out
for 1-4 hours at 37°C, then quenched using 0.5% SDS, 15 mM EDTA, and 1 mg/mL
proteinase K for 30 minutes at 37°C. Reaction products were separated on 1.5%
agarose gels in Tris-acetate buffer and imaged using a Typhoon (Amersham) imager.
Gels were then stained with ethidium bromide and imaged using a Gel Doc (Bio-Rad)
imager. Reaction products were quantified by ImageJ and data analysis was carried out
in Prism (GraphPad). Significance was evaluated by two-way ANOVA with P values
reported from Tukey’s multiple comparisons test. Dose-response curve fits were
performed in Prism (GraphPad) using a three-parameter logistic regression with the Hill
slope fixed at -1. The integrase inhibitor raltegravir was a gift from Merck.

Aggregation assay for ALLINIs
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Assays were performed as previously described (Gupta et al. 2016, 2014) with
some modification. Final reaction conditions were 20 mM HEPES-NaOH pH 7.5, 15 μM
IN, 250-1000 mM NaCl, 7 mM CHAPS, and 30 μM ALLINI. The ALLINIs BI-224436,
BI-D,

and

CX04328

(HIV-1

integrase

inhibitor

2)

were

purchased

from

MedChemExpress and resuspended in DMSO. Turbidity was measured after 20 minutes
as the absorbance of the reaction solution at 405 nm in a plate reader (Victor 3V, Perkin
Elmer). Significance was evaluated by two-way ANOVA with P values reported from
Tukey’s multiple comparisons test.

Size-exclusion chromatography in-line with multi-angle light scattering
(SEC-MALS)
Absolute molecular weights were determined by multi-angle light scattering
coupled with refractive interferometric detection (Wyatt Technology Corporation) and a
Superdex 200 10/300 column (GE Healthcare) at 25°C equilibrated in 20 mM
HEPES-NaOH pH 7.5, 500 mM - 1 M NaCl, 7 mM CHAPS, 10 μM ZnOAc2, and 10 μM
β-mercaptoethanol, as previously described (Gupta et al. 2010).

Sedimentation velocity analytical ultracentrifugation (SV-AUC)
SV-AUC experiments were performed at 25°C with an XL-A analytical
ultracentrifuge (Beckman-Coulter) and a TiAn60 rotor with two-channel charcoal-filled
epon centerpieces and quartz windows. Experiments were performed in 20 mM
HEPES-NaOH pH 7.5, 1 M NaCl, 7 mM CHAPS, 10 μM ZnOAc2, and 10 μM
β-mercaptoethanol. Complete sedimentation velocity profiles were collected every 30 s
for 200 boundaries at 40,000 rpm. Data were fit using the c(s) distribution model of the
Lamm equation as implemented in the program SEDFIT (Schuck 2000). After optimizing
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meniscus position and fitting limits, the sedimentation coefficients and best-fit frictional
ratio (f/f0) were determined by iterative least squares analysis. Sedimentation coefficients
were corrected to s20,w based on the calculated solvent density (ρ) and viscosity (η)
derived from chemical composition by the program SEDNTERP (Hayes et al. 2003).

Sedimentation equilibrium analytical ultracentrifugation (SE-AUC)
SE-AUC experiments were performed with an XL-A analytical ultracentrifuge
(Beckman-Coulter)

and

a

TiAn60 rotor with two-channel charcoal-filled epon

centerpieces and quartz windows. Data were collected at 4°C with detection at 280 nm
at multiple concentrations in 20 mM HEPES-NaOH pH 7.5, 1 M NaCl, 7 mM CHAPS, 10
μM ZnOAc2, and 10 μM β-mercaptoethanol. Analyses were carried out using global fits
to data acquired at multiple speeds for each concentration with strict mass conservation
using the program SEDPHAT (Vistica et al. 2004). Error estimates for equilibrium
constants were determined from a 1,000-iteration Monte Carlo simulation. The partial
specific volume ( v ), solvent density (ρ), and viscosity (η) were derived from chemical
composition by SEDNTERP (Hayes et al. 2003). SE-AUC data are summarized in Table
4.2.
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Supporting Information for Chapter 5
IN·LEDGF coexpressions
Expression plasmids containing full-length or truncated IN 1F constructs (Eilers
et al. 2020) and LEDGFIBD (Ciuffi et al. 2006) were transformed into E. coli BL21(DE3)
with or without a pET28a plasmid encoding the Ulp1 protease (Mossessova and Lima
2000) with an N-terminal, thrombin-cleavable polyhistidine tag. The IN 1F constructs
contain an N-terminal His7-FLAG-SUMO tag, that, when co-expressed with Ulp1 in vivo
or cleaved by Ulp1 in vitro, is cleaved off, liberating IN with a native phenylalanine at
position 1. The LEDGFIBD contains a C-terminal Mxe intein, chitin-binding domain, and
polyhistidine tag. Since IN 1F constructs lack a chitin-binding domain, purification by
chitin affinity selectively binds LEDGFIBD and its binding partners. NL4-3 IN was used for
co-expressions of full-length IN with LEDGFIBD. For coexpressions of full-length IN or
INNTD-CCD

with

LEDGFIBD

and

Ulp1,

NL4-3

INT124N was

used.

T124N

is

a

commonly-occurring polymorphism (B. T. Foley et al. 2018) that has been observed to
be positively selected in the presence of ALLINIs (Sharma et al. 2014; Gupta et al. 2016;
Hoyte et al. 2017). Coexpressions were expressed as described previously, with some
modification (Ciuffi et al. 2006; Diamond and Bushman 2006; Gupta et al. 2014, 2010).
Cultures of E. coli BL21(DE3) containing expression plasmids was grown in 800mL of
2xYT with 10 µM ZnSO4 and 2 mM MgSO4 at 37°C to an optical density of 1.8-2.2. After
addition of isopropyl-β-D-1-thiogalactopyranoside (IPTG), expression was allowed to
continue for 5 hours at 20°C. Bacteria were then pelleted and frozen at -80°C.

IN·LEDGF copurifications
IN and LEDGF were purified as previously described (Eilers et al. 2020)
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Lysates of IN·LEDGFIBD coexpressions in 20 mM sodium/potassium phosphate
pH 7.0 and 300 mM NaCl and protease inhibitor were purified using chitin (New England
Biolabs) resin. LEDGFIBD was liberated by intein cleavage in the presence of 5mM
CHAPS with 100 mM β-mercaptoethanol at 4°C overnight. A second chitin purification
step separated the affinity tag from liberated LEDGFIBD and bound IN. IN·LEDGFIBD
complexes were concentrated at 4°C in an Amicon Ultra-15 (Millipore) before injection
onto a Superdex 75 HiLoad 16/60 column (GE Healthcare) at room temperature.
Complexes were eluted isocratically in 20 mM HEPES-NaOH pH 7.5, 300 mM NaCl, 5
mM CHAPS, 10 µM ZnOAc2, and 5 mM β-mercaptoethanol or dithiothreitol and
concentrated at 4°C in an Amicon Ultra-15 (Millipore).

Size-exclusion chromatography in-line with multi-angle light scattering
(SEC-MALS)
Complexes were analyzed by separation on a Superdex 200 10/300 column (GE
Healthcare) at 25°C, eluted isocratically in 20 mM HEPES-NaOH pH 7.5, 300 mM NaCl,
5 mM CHAPS, 10 μM ZnOAc2, and 10 μM β-mercaptoethanol. Absolute molecular
weights were determined by multi-angle light scattering coupled with refractive
interferometric detection (Wyatt Technology Corporation), as previously described
(Gupta et al. 2010).

Integrase strand transfer assay
Assays were performed as previously described (Eilers et al. 2020). Final assay
conditions were approximately 3 μM IN, 1.5 μM LEDGFIBD (as estimated from A280 and
SDS-PAGE), 20 mM HEPES-NaOH pH 7.5, 0.5 μM Alexafluor 488-labeled LTR
substrate, 150 mM NaCl, 10 mM MgCl2, and 10 μM Zn(OAc)2. Pickle products were
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analyzed on 1.5% agarose gels, imaged for fluorescence and then stained with ethidium
bromide.

Turbidity assay for integrase stability
We have previously reported an integrase aggregation assay based on the
measurement of turbidity in solution (Gupta et al. 2014, 2016; Eilers et al. 2020). This
assay was adapted to measure the precipitation of integrase in low ionic strength
conditions. Final conditions were 30 µM IN, 10 µM LTR DNA, 20 mM HEPES pH 7.5,
and 7 mM CHAPS for IN alone and IN·LEDGFIBD complexes. CHAPS was dialyzed out
of IN·LEDGFIBD complexes before mixing with LTR DNA, further emphasizing the
solubilizing effect of the LTR DNA. Turbidity was measured for 30 minutes as the
absorbance of the reaction solution at 405 nm in a plate reader (Victor 3V, Perkin Elmer)
and plotted throughout the course of the experiment (Figure 5.4a,b) or as turbidity at the
end of the 30 minute experiment (Figure 5.4c).

Intasome preparations
Intasomes were prepared as previously described (Hare, Gupta, et al. 2010;
Pandey et al. 2014; Yin et al. 2016; Ballandras-Colas et al. 2016, 2017; Passos et al.
2017, 2020; Cook et al. 2020) with some modification. DNA templates were prepared by
mixing oligonucleotides at equimolar ratios in the presence of 10 mM Tris, 0.1 mM
EDTA, and 100 mM NaCl. Mixtures were heated to 95°C and then slowly cooled. For low
ionic strength dialysis, mixtures of ~50 μM IN, 25 μM LEDGFIBD (as estimated from A280
and SDS-PAGE), and 6.6 μM 3WJ DNA (Supplemental Figure 5.1b) were dialyzed to 5
mM HEPES-NaOH pH 7.5, 100 mM NaCl, 10 μM ZnSO4, and 5 mM DTT in 3K MWCO
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dialysis containers (Thermo Scientific) at 4°C overnight. Samples were briefly
centrifuged to remove precipitated protein and DNA. Samples were then taken for
chemical crosslinking, polyacrylamide EMSA, and SDS-PAGE analysis. For experiments
that were spiked to low ionic strength, mixtures of 0.5-5 μM IN, 1-3 μM LEDGFIBD (where
indicated), and 0.5 μM fluorescently labeled oligonucleotide (Supplemental Figure 5.1c)
in 20 mM HEPES-NaOH pH 7.5, 10 mM MgCl2 or CaCl2 (where indicated), and 2 μM or
20 μM raltegravir (where indicated). The integrase inhibitor raltegravir was a gift from
Merck. Mixtures were incubated at 37°C for 1 hour. Samples were then taken for
agarose EMSA.

Chemical Crosslinking
For crosslinking experiments, the crosslinkers disuccinimidyl glutarate (DSG) and
disuccinimidyl suberate (DSS) were resuspended in DMSO and added to a final
concentration of 0.25 mM (~5x molar excess over IN) and 1 mM (~20x molar excess
over IN). Crosslinking was allowed to proceed for 30 minutes at room temperature
before quenching with 25 mM final Tris pH 7.5. for 15 minutes at room temperature.
Samples were analyzed by SDS-PAGE.

Agarose electrophoretic mobility shift assay
Samples were taken from low ionic strength intasome preparations and loading
buffer containing glycerol and bromophenol blue was added. Samples were separated
on 3% agarose gels in 0.5x Tris-Borate running buffer. Ethidium bromide-free buffers
and apparatus were used. Gels were run at 15 v/cm for 30 minutes and then imaged for
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fluorescence using a Typhoon (Amersham) imager. Gels were then stained with ethidium
bromide and imaged using a Gel Doc (Bio-Rad) imager.

Polyacrylamide electrophoretic mobility shift assay
Samples were taken from overnight dialysis intasome preparations and loading
buffer containing glycerol and bromophenol blue was added. Samples were separated
on 6% polyacrylamide gels in 1x Tris-Borate-EDTA running buffer. Gels were run at 5-10
v/cm for 2 hours at 4°C and then stained with Gel Star (Lonza) for detection of nucleic
acid or coomassie blue for detection of protein. Gel Star-stained gels were imaged using
a Typhoon (Amersham) imager, and coomassie-stained gels were imaged using a Gel
Doc (Bio-Rad) imager.

Supplemental Figures
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